WO2025047047A1 - Silk fibroin film and anti-adhesion material containing same - Google Patents
Silk fibroin film and anti-adhesion material containing same Download PDFInfo
- Publication number
- WO2025047047A1 WO2025047047A1 PCT/JP2024/021523 JP2024021523W WO2025047047A1 WO 2025047047 A1 WO2025047047 A1 WO 2025047047A1 JP 2024021523 W JP2024021523 W JP 2024021523W WO 2025047047 A1 WO2025047047 A1 WO 2025047047A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- silk fibroin
- film
- water
- adhesion
- kda
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08H—DERIVATIVES OF NATURAL MACROMOLECULAR COMPOUNDS
- C08H1/00—Macromolecular products derived from proteins
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L89/00—Compositions of proteins; Compositions of derivatives thereof
Definitions
- the present invention relates to a silk fibroin film for use in an anti-adhesion material and to an anti-adhesion material containing the same.
- adhesions can form after surgery, bonding tissues and organs that should normally be separate and becoming inseparable.
- the formation of adhesions can necessitate a second surgery to remove the adhesions, which can take a lot of time and effort, and can even cause new damage during the removal process. It can also lead to complications such as intestinal obstruction and infertility.
- anti-adhesion materials have been developed that physically prevent contact between tissues or organs by applying them to the surfaces of tissues or organs.
- Anti-adhesion materials have been developed in the form of films or sprays, and film-type anti-adhesion materials are used clinically in the fields of gastrointestinal surgery and obstetrics and gynecology.
- film-type anti-adhesion materials include Seprafilm (registered trademark), which contains hyaluronic acid and carboxymethylcellulose, and Tenaleaf (registered trademark), which contains gelatin.
- Seprafilm registered trademark
- Tenaleaf registered trademark
- Patent Document 1 JP Patent Publication No. 2016-517443 discloses a low molecular weight silk fibroin composition containing a population of silk fibroin fragments having a certain range of molecular weights, wherein 15% or less of the total number of the silk fibroin fragments in the population have a molecular weight exceeding 200 kDa, and at least 50% of the total number of the silk fibroin fragments in the population have a molecular weight within a specified range, the specified range being between a lower limit of about 3.5 kDa or more and an upper limit of about 120 kDa or less, and the composition is described as being usable in the form of a film and for medical purposes.
- Patent Document 2 U.S. Pat. No. 9,427,499 discloses a silk fibroin matrix in which at least a portion of a first surface is selectively modified with poly(ethylene glycol) (PEG) at a density of about 75 to about 750 ⁇ g PEG/ cm2 silk fibroin matrix, and describes that the silk fibroin matrix can be used as an adhesion barrier.
- PEG poly(ethylene glycol)
- Patent Document 1 describes that low molecular weight silk fibroin can be made more water soluble, it does not describe the use of low molecular weight silk fibroin compositions as adhesion prevention materials.
- Patent Document 2 also describes that modifying the surface of a silk fibroin matrix with PEG suppresses the adhesiveness and proliferation-promoting properties of mesenchymal stem cells and fibroblasts, respectively, but it is the PEG on the surface that contributes to these inhibitions, and the paper does not find any effect due to the structure of the silk fibroin itself. Furthermore, the paper did not evaluate the adhesion prevention effect in vivo.
- the object of the present invention is therefore to provide a silk fibroin film suitable for use as an adhesion prevention material.
- a silk fibroin film the surface of which dissolves in water in a short period of time, has excellent adhesion prevention effects, leading to the completion of the present invention.
- the silk fibroin film is an anti-adhesion material, in which at least the surface of the silk fibroin film dissolves in water within 24 hours (preferably within 12 hours, more preferably within 1 hour, and even more preferably within 10 minutes) after being floated on water.
- a silk fibroin film in which, in measurement of the contact angle of water on the film surface, the change in contact angle from when a 5 ⁇ L droplet of ultrapure water is dropped on the film surface until 5 seconds later is ⁇ 5°/sec or less (preferably ⁇ 20 to ⁇ 5°/sec, more preferably ⁇ 15 to ⁇ 5°/sec, particularly preferably ⁇ 10 to ⁇ 5°/sec).
- a silk fibroin film comprising silk fibroin having a weight average molecular weight of 40 to 150 kDa (preferably 50 to 120 kDa, more preferably 55 to 100 kDa) and a molecular weight distribution (PDI) of 1 to 10 (preferably 1.2 to 9, more preferably 1.5 to 8).
- PDI molecular weight distribution
- An adhesion preventing material comprising the silk fibroin film according to any one of aspects 1 to 7.
- the present invention relates to a method for producing a silk fibroin film for use as an anti-adhesion material, the method comprising the steps of: dissolving refined silk fibroin in a solvent and reacting the resulting solution with an alkali treating agent; and forming a film from the alkali-treated silk fibroin.
- the range may include ⁇ 10% of the numerical value, and preferably ⁇ 5%.
- the silk fibroin film of the present invention can prevent adhesions between tissues and organs after surgery, and because it contains ingredients different from conventional film-type adhesion barriers, it can be used as an adhesion barrier of choice depending on the patient's sensitivity.
- 1 is a graph showing plot data of the change over time in the contact angle of water of the silk fibroin film of Example 4 and an approximation line of the data from 0 to 5 seconds.
- FIG. 13 is a box plot showing the adhesion score results when saline, the silk fibroin film of Comparative Example 4 (HMW), the silk fibroin film of Example 4 (LMW), Seprafilm, and Tenaleaf were applied, respectively.
- 13 is a photograph showing the cecum and abdominal wall (adhesion score: 0) two weeks after implantation of the silk fibroin film of Example 4.
- 13 is a photograph showing the cecum and abdominal wall (adhesion score: 5) two weeks after implantation of the silk fibroin film of Comparative Example 4.
- 13 is a photograph showing adhesions between the cecum and abdominal wall two weeks after implantation of the silk fibroin film of Comparative Example 4.
- 1 is a stained photograph showing the state of the abdominal wall and cecum two weeks after application of saline to the laceration in Comparative Example 1.
- the scale bar indicates 1 mm.
- 1 is a stained photograph showing the state of the abdominal wall and cecum two weeks after application of the silk fibroin film (HMW) of Comparative Example 4 to a laceration wound.
- the scale bar indicates 1 mm.
- 1 is a stained photograph showing the state of the abdominal wall and cecum two weeks after application of the silk fibroin film (LMW) of Example 4 to a laceration wound.
- the scale bar indicates 1 mm.
- 1 is a stained photograph showing the condition of the abdominal wall and cecum two weeks after application of Seprafilm to the laceration.
- the silk fibroin film dissolves in water at least at the surface of the silk fibroin within 24 hours after floating on water.
- the dissolution of the film surface in water can be confirmed by observing the method described in the examples below, and by confirming that the square drawn with an oil pen (black) on the surface of a square film with sides of 1 cm and the six straight lines (line width 1 mm) of the square drawn with an oil pen are all broken.
- the film surface dissolves in water
- each of the six straight lines drawn with an oil pen on the first surface peels off from the film and separates from each other, and each straight line is broken by cracks. Therefore, the water solubility of the film surface can be evaluated by confirming that the straight lines drawn with an oil pen peel off together with the film surface after the film is floated on water, and finally all six straight lines are broken.
- the film surface of the lower surface (second surface) of the film can also be considered to dissolve.
- the film surface needs to dissolve in water within 24 hours, and the portions other than the film surface may or may not dissolve. Therefore, the entire film may dissolve in water within 24 hours.
- the high water solubility of the film surface of the silk fibroin film can prevent the film surface from being in contact with cells, fibrin, etc. for a long time, and the adhesion of cells, fibrin, etc. is inhibited, or the cells, fibrin, etc. that are intended to be adhered or adsorbed are peeled off together with the film surface, so that the adhesion prevention effect can be exerted.
- the time for which the film surface dissolves in water is preferably within 12 hours after floating on water, more preferably within 1 hour, and even more preferably within 10 minutes.
- the lower limit of the time for which the film surface dissolves in water is not particularly limited, but may be, for example, 1 second or more, and from the viewpoint of easy re-application, it may be preferably 30 seconds or more, more preferably 50 seconds or more, and particularly preferably 100 seconds or more.
- the water solubility of the silk fibroin film after immersion in water and incubation at 25°C for 24 hours may be 50% or more, preferably 70% or more, more preferably 80% or more, and even more preferably 90% or more.
- the upper limit of the water solubility after 24 hours after immersion in water is not particularly limited, and may be 100% or less.
- the water solubility after 24 hours is a value measured by the method described in the examples below.
- the water solubility of the silk fibroin film after immersion in water and incubation at 25°C for 1 hour may be 100% or less, preferably 99% or less, and more preferably 98% or less.
- the lower limit of the water solubility after immersion in water for 1 hour is not particularly limited, but from the viewpoint of the effect of decomposition and absorption as an adhesion prevention material, for example, it may be 45% or more, preferably 55% or more, more preferably 65% or more, and even more preferably 75% or more.
- the change in the contact angle from dropping a 5 ⁇ L drop of ultrapure water on the film surface until 5 seconds later may be -5°/sec or less. Since the surface of the silk fibroin film is water-soluble, when a drop of water is dropped on the film surface, the film surface dissolves in the drop of water, causing the contact angle to change. It is preferable that the contact angle of water changes more negatively (larger in absolute value) in a short time.
- the change in the contact angle may be preferably -20 to -5°/sec, more preferably -15 to -5°/sec, and particularly -10 to -5°/sec.
- the silk fibroin film has a water-soluble film surface, but does not necessarily have to show high wettability immediately after contact with water.
- the contact angle of water may be large immediately after a water droplet is dropped on the film surface, but the film may have the above-mentioned contact angle change due to its water-solubility.
- the contact angle when a water droplet is dropped on the film surface (0 seconds) may be 50 to 90°, preferably 55 to 85°, and more preferably 60 to 80°.
- the water contact angle of a silk fibroin film at 0 seconds is a value measured by the method described in the Examples below.
- the time when a water droplet is dropped on the film surface is set to 0 seconds, and the measurement data of the contact angle from 0 to 5 seconds is linearly approximated by the least squares method, and the intercept of the obtained line is shown.
- the silk fibroin film contains silk fibroin.
- Silk fibroin mainly contains glycine, alanine, serine, and tyrosine, and is composed of a crystalline portion in which the molecules are regularly arranged and an amorphous portion in which the molecules are randomly arranged, and is generally known as a type of fibrous protein.
- the raw material is not particularly limited, and silk fibroin can be obtained from, for example, a silk raw material described later.
- silk fibroin may be chemically modified within a range that does not impair the effects of the present invention.
- the term "silk fibroin" when used, the definition includes chemically modified silk fibroin, although the silk fibroin present on the film surface may be silk fibroin that is not modified with polyethylene glycol (PEG).
- PEG polyethylene glycol
- the silk fibroin film preferably contains unmodified silk fibroin in order to utilize the properties of silk fibroin as an adhesion prevention material.
- unmodified silk fibroin means silk fibroin that has not been subjected to a reaction to introduce functional groups or crosslinking or a grafting reaction, and the side chains of the amino acid residues that constitute the silk fibroin have not been chemically modified.
- the silk fibroin may have a weight average molecular weight (Mw) of 150 kDa or less (e.g., 10 to 150 kDa), preferably 120 kDa or less, more preferably 100 kDa or less, and even more preferably 90 kDa or less.
- Mw weight average molecular weight
- the weight average molecular weight of silk fibroin is a value measured by the method described in the Examples below.
- the number average molecular weight (Mn) of silk fibroin may be 80 kDa or less (e.g., 1 to 70 kDa), preferably 60 kDa or less, more preferably 50 kDa or less, even more preferably 40 kDa or less, and even more preferably 30 kDa or less. There is no particular limit to the lower limit of the number average molecular weight, but it may be, for example, 1 kDa or more, preferably 5 kDa or more.
- the number average molecular weight of silk fibroin is a value measured by the method described in the Examples below.
- the molecular weight distribution of silk fibroin may be 1 to 10 (e.g., 1 to 4), preferably 1.2 to 9 (e.g., 1.2 to 3.8), more preferably 1.5 to 8 (e.g., 1.5 to 3.5), even more preferably 2 to 6, and particularly preferably 3 to 5.
- the molecular weight distribution indicates the polydispersity index (PDI) calculated by dividing the weight average molecular weight (Mw) by the number average molecular weight (Mn).
- the peak top molecular weight (Mp) of silk fibroin may be 250 kDa or less (e.g., 10 to 250 kDa), preferably 150 kDa or less, more preferably 100 kDa or less, even more preferably 80 kDa or less, particularly preferably 60 kDa or less, and even more preferably 50 kDa or less.
- the lower limit of the peak top molecular weight is not particularly limited, but may be, for example, 5 kDa or more, preferably 10 kDa or more.
- the peak top molecular weight refers to the molecular weight corresponding to the position of the peak top detected in a chromatogram, and is a value measured by the method described in the Examples below.
- Preferred silk fibroin films include silk fibroin films containing silk fibroin having a weight average molecular weight of 40 to 150 kDa, preferably 50 to 120 kDa, more preferably 55 to 100 kDa, and a molecular weight distribution (PDI) of 1 to 10 (e.g., 1 to 4), preferably 1.2 to 9 (e.g., 1.2 to 3.8), more preferably 1.5 to 8 (e.g., 1.5 to 3.5).
- the silk fibroin film may also have the various characteristics described above.
- the moisture content of the silk fibroin film may be 30% or less, preferably 1-30%, more preferably 3-20%, and even more preferably 5-15%.
- the moisture content of the silk fibroin film is the weight ratio of water contained in the silk fibroin film (the ratio of the weight of water contained to the weight of the silk fibroin film), and is a value measured by the method described in the examples below.
- the silk fibroin film may contain components other than silk fibroin and water (e.g. additives such as colorants), but the silk fibroin content may be 90% or more by weight of solid matter, preferably 95% or more, more preferably 98% or more, and even more preferably 99.9% or more.
- the silk fibroin film contains a coloring agent, this can be advantageous as it makes it easier for medical professionals to visually confirm the areas on the surface of organs, etc. where the adhesion prevention material has been applied.
- the thickness of the silk fibroin film can be appropriately selected depending on the clinical field and location of use of the adhesion prevention material, and can be selected from a wide range, for example, from 1 ⁇ m to 5 mm. However, when considering use in the fields of gastrointestinal surgery and obstetrics and gynecology, the thickness of the silk fibroin film may be, for example, 1 ⁇ m to 1 mm, preferably 5 to 200 ⁇ m (e.g., 7 to 180 ⁇ m), and more preferably 10 to 150 ⁇ m.
- the silk fibroin film may have a puncture strength of 0.01 N or more (e.g., 0.01 to 5 N), preferably 0.05 N or more, and more preferably 0.1 N or more. If the puncture strength is within the above range, it is easy to handle as an adhesion prevention material. There is no particular upper limit to the puncture strength of the silk fibroin film, but it may be, for example, 5 N or less.
- the puncture strength of the silk fibroin film is a value measured by the method described in the Examples below.
- Silk fibroin films are used as adhesion inhibitors, including the silk fibroin film.
- adhesion inhibitor refers to a biomaterial that is applied to sites of organ or tissue damage caused by trauma, dissected surfaces of organs after surgery, and tissue surfaces surrounding organs after surgery, where adhesions may occur, for the purpose of suppressing "adhesion," a phenomenon in which tissue surfaces or organ surfaces that should be separated from each other become bonded to other tissue surfaces or organ surfaces and cannot be separated due to inflammation after surgery or the like.
- Trauma refers to damage to organs or tissues caused by external forces (mechanical, physical, or chemical).
- organ refers to an internal organ, which is an anatomical unit with its own structure and specific function, such as the brain, heart, esophagus, stomach, bladder, small intestine, large intestine, liver, kidneys, pancreas, spleen, uterus, etc.
- tissue refers to a unit that performs a certain function by combining related cells or substances produced by cells, and examples of such tissue include skin, muscle, tendon, bone, joint, ligament, blood vessel, pancreatic islet, and cornea.
- tissue surface refers to the surface that is exposed to the inside of the body after part of a tissue or organ is removed or peeled off during surgery or other procedures.
- the adhesion prevention material can be used to prevent adhesion of any tissue or organ where adhesion may occur in surgery in clinical fields such as gastrointestinal surgery, cardiac surgery, orthopedics, and obstetrics and gynecology, and is particularly suitable for use in surgery in gastrointestinal surgery and obstetrics and gynecology.
- it can be used by applying it to damaged areas of the intestine or peritoneum, or damaged areas of the uterus or appendages. It can also be used not only in human surgery, but also in surgery on animals (non-humans) such as pets.
- non-human animals include non-human mammals, such as apes, other primates, mice, rats, hamsters, guinea pigs, horses, cows, pigs, sheep, goats, dogs, cats, and rabbits.
- adhesion prevention does not only mean completely preventing the occurrence of adhesions, but also includes reducing the degree, range, and frequency of adhesions.
- the anti-adhesion material may consist essentially of the silk fibroin film, or it may be a laminate that includes a support necessary for maintaining the shape of the film.
- the adhesion prevention material may be preferably applied to the dissected surface of an organ or tissue after surgery and to the surface of tissue surrounding the organ after surgery during the finishing process of a surgical procedure such as an abdominal surgery.
- the method for producing a silk fibroin film may include an alkali treatment step of dissolving refined silk fibroin in a solvent and reacting it with an alkali treatment agent, and a step of forming a film from the alkali-treated silk fibroin.
- cocoons and raw silk produced by insects can be used, and there is no particular limitation as long as the raw material for silk contains fibroin and sericin.
- Silk fibroin from which sericin has been removed can be obtained by refining the raw silk material.
- Silk fibroin can also be obtained from silk glands.
- Refining can be performed by known methods, and examples of such methods include a method of removing sericin by swelling it using an alkaline refining agent such as sodium carbonate, sodium silicate, or sodium phosphate, a method of decomposing sericin using a sericin-degrading enzyme, and a method of removing sericin by decay. Refining using an alkaline refining agent is preferred from the viewpoint of ease of setting conditions.
- the main purpose of scouring is to remove sericin, and in order to suppress the decomposition of silk fibroin, the scouring time using an alkaline scouring agent varies depending on the type of silk raw material and alkaline scouring agent, but may be 5 to 60 minutes, preferably 10 to 50 minutes, and more preferably 15 to 45 minutes.
- the refined silk fibroin is subjected to an alkali treatment to hydrolyze the silk fibroin and improve its water solubility.
- an alkali treatment step it is preferable to carry out the hydrolysis of silk fibroin in an alkali treatment step.
- the alkali treatment can be carried out by dissolving silk fibroin in a solvent and reacting it with an alkali treatment agent (e.g., an alkali metal hydroxide such as sodium hydroxide or potassium hydroxide, or ammonia, etc.).
- an alkali treatment agent e.g., an alkali metal hydroxide such as sodium hydroxide or potassium hydroxide, or ammonia, etc.
- silk fibroin may be dissolved in a neutral salt solution containing a neutral salt such as lithium bromide or calcium chloride.
- Silk fibroin may be dissolved and alkali treatment may be carried out at the same time using a mixed solution containing a neutral salt and an alkali treatment agent, or silk fibroin may be dissolved in a neutral salt solution and then an alkali treatment agent may be added to carry out the alkali treatment.
- the concentration of the neutral salt in the solution may be, for example, 3 to 15 M, preferably 4 to 14 M, and more preferably 3 to 12 M.
- the concentration of the alkali metal hydroxide in the solution may be, for example, 0.05 to 2 M, and preferably 0.08 to 1.5 M.
- the concentration of ammonia in the solution may be, for example, 0.05 to 1.5 M, and preferably 0.1 to 1 M.
- the temperature of the alkali treatment may be 40°C or less (for example, 5 to 40°C), preferably 10°C to 40°C, and more preferably 15°C to 35°C.
- the time for carrying out the alkali treatment may be more than 3 hours, preferably 4 hours or more, more preferably 10 hours or more, and even more preferably 15 hours or more.
- the upper limit of the time for carrying out the alkali treatment is not particularly limited, but may be, for example, 48 hours or less. In this specification, the time for carrying out the alkali treatment means the time during which the silk fibroin is in contact with the alkali treatment agent.
- a mixed solution containing a neutral salt and an alkali treatment agent when used, it indicates the time from adding the mixed solution to the silk fibroin (or adding the silk fibroin to the mixed solution), and when an alkali treatment agent is added after dissolving the silk fibroin in a neutral salt solution, it indicates the time from adding the alkali treatment agent.
- the silk fibroin obtained by alkali treatment may have various molecular weights (Mw, Mn, PDI, and Mp) within the above-mentioned ranges.
- the method for producing a silk fibroin film may include a step of forming a silk fibroin film having a weight-average molecular weight (Mw) of 150 kDa or less (preferably 120 kDa or less, more preferably 100 kDa or less, and even more preferably 80 kDa or less).
- the neutral salts and the alkaline treatment agent may be removed by known methods such as dialysis or ultrafiltration. From the viewpoint of using it as a biomaterial, it is preferable to purify and sterilize the silk fibroin before membrane formation (film formation) in order to remove impurities other than the neutral salts and the alkaline treatment agent.
- known methods such as autoclave sterilization and filter sterilization can be used, but autoclave sterilization is preferable.
- a silk fibroin film can be obtained by forming a membrane using an aqueous silk fibroin solution (preferably an aqueous silk fibroin solution after purification and/or sterilization).
- the concentration of the aqueous silk fibroin solution may be adjusted according to the desired thickness and physical properties of the film.
- the concentration of the aqueous silk fibroin solution may be 0.1-10% (w/v), preferably 0.5-8% (w/v), and more preferably 1-6% (w/v).
- Silk fibroin can be formed into a film by known film-forming methods such as casting and coating.
- a silk fibroin film can be obtained by casting or applying an aqueous solution of silk fibroin onto a substrate and then drying it.
- the measurement sample was 500 ⁇ L of a silk fibroin aqueous solution adjusted to a concentration of 1% (w/v). Using this measurement sample, measurements were performed by gel filtration chromatography (GFC) using the following measurement device and conditions. The weight average molecular weight (Mw), number average molecular weight (Mn), molecular weight distribution (PDI), and peak top molecular weight (Mp) of silk fibroin were calculated using molecular weight markers included in the low molecular weight (Low Molecular Weight; LMW) Gel Filtration Calibration Kits and the high molecular weight (High Molecular Weight; HMW) Gel Filtration Calibration Kits (both manufactured by Cytiva) as standard substances.
- GFC gel filtration chromatography
- Cytiva GFC device Cytiva GFC device "AKTAgo” Separation column: Cytiva "HiLoad16/600 Superdex 200pg” Mobile phase: 20 mM sodium phosphate buffer containing 500 mM sodium chloride (pH: 7.4) ⁇ Flow rate: 1mL/min Temperature: Room temperature (24.0°C) or lower. When simply referring to room temperature, 24.0°C is used as the representative value.
- the water solubility was taken as 100%.
- the tube was then left to stand in a constant temperature dryer (As One, "KM-600V") set at 50°C and incubated overnight to evaporate the moisture retained in the remaining film, and the weight of the tube and the dried silk fibroin film combined was measured (the weight at this time was referred to as the "tube + dried film weight”).
- the thickness ( ⁇ m) of the silk fibroin film was measured using a digital micrometer (Nikon Corporation, "MFC-101A"). The zero point was set with the measurement head lowered to the pedestal. Then, the silk fibroin film sample stored overnight or longer in an indoor environment was placed on the pedestal, and the measurement head was lowered to the sample to measure the thickness of the silk fibroin film. In the same manner, measurements were taken for each of the three individually prepared samples, and the average value of these measurements was calculated as the thickness ( ⁇ m) of the silk fibroin film.
- Example 1 Silkworm cocoons were cut into pieces and degummed in a boiling 0.02 M aqueous solution of sodium carbonate for 30 minutes to obtain silk fibroin.
- 3 g of the refined silk fibroin was immersed in a mixed aqueous solution (50 mL) containing 9 M lithium bromide and 0.1 M sodium hydroxide (NaOH) and left at room temperature for 1 to 6 hours.
- this mixed aqueous solution was stirred at room temperature for 17 hours, dissolving the silk fibroin in the mixed aqueous solution and subjecting it to an alkali treatment to obtain an aqueous silk fibroin solution.
- the obtained silk fibroin aqueous solution was dialyzed in deionized water using a dialysis membrane (molecular weight cutoff: 6-8k). Each dialysis was carried out at room temperature for 6-12 hours, and this was repeated six times (bath ratio: 160 times). This removed the lithium bromide and sodium hydroxide contained in the silk fibroin aqueous solution.
- the silk fibroin aqueous solution was concentrated by air drying at room temperature. Concentration by air drying was continued until the volume of the silk fibroin aqueous solution was reduced to 1/5 to 1/3.
- the concentrated silk fibroin aqueous solution was subjected to autoclave sterilization using an autoclave device (Tomy Seiko Co., Ltd., "LBS-245"). Autoclave sterilization was performed twice at 121°C for 20 minutes. All subsequent treatments were performed under sterile conditions.
- the silk fibroin aqueous solution after autoclave sterilization was centrifuged (40,000 x g, 20°C, 30 minutes) using a centrifuge (Beckman Coulter, "Avanti 20I") to remove precipitated insoluble matter.
- the silk fibroin aqueous solution was freeze-dried and the concentration was adjusted to 1% (w/v).
- Example 2 After freeze-drying, a silk fibroin aqueous solution was adjusted to a concentration of 5% (w/v), and a silk fibroin film was obtained in the same manner as in Example 1, except that 3 mL of the silk fibroin aqueous solution was spread in a polystyrene petri dish.
- Example 4 After freeze-drying, a silk fibroin aqueous solution was adjusted to a concentration of 5% (w/v), and a silk fibroin film was obtained in the same manner as in Example 1, except that 6 mL of the silk fibroin aqueous solution was spread in a polystyrene petri dish.
- Example 5 After freeze-drying, a silk fibroin aqueous solution was adjusted to a concentration of 5% (w/v), and a silk fibroin film was obtained in the same manner as in Example 1, except that 10 mL of the silk fibroin aqueous solution was spread in a polystyrene petri dish.
- Example 1 A silk fibroin film was obtained in the same manner as in Example 1, except that 3 g of the refined silk fibroin was immersed in a 9 M lithium bromide aqueous solution (50 mL) that did not contain NaOH.
- Example 2 A silk fibroin film was obtained in the same manner as in Example 2, except that 3 g of the refined silk fibroin was immersed in a 9 M lithium bromide aqueous solution (50 mL) that did not contain NaOH.
- Example 3 A silk fibroin film was obtained in the same manner as in Example 3, except that 3 g of the refined silk fibroin was immersed in a 9 M lithium bromide aqueous solution (50 mL) that did not contain NaOH.
- Example 4 A silk fibroin film was obtained in the same manner as in Example 4, except that 3 g of the refined silk fibroin was immersed in a 9 M lithium bromide aqueous solution (50 mL) that did not contain NaOH.
- Example 5 A silk fibroin film was obtained in the same manner as in Example 5, except that 3 g of the refined silk fibroin was immersed in a 9 M lithium bromide aqueous solution (50 mL) that did not contain NaOH.
- one film-type adhesion inhibitor (2 cm x 2 cm) was attached to each of the wounds on the cecum surface and abdominal wall surface, and the wound was closed.
- the film-type adhesion inhibitors used were the silk fibroin film of Example 4, the silk fibroin film of Comparative Example 4, Seprafilm (manufactured by Baxter), and Tenalef (manufactured by Gunze Co., Ltd.).
- Four rats were prepared each with the silk fibroin film of Example 4, the silk fibroin film of Comparative Example 4, and Tenaleaf, and five rats were prepared with Seprafilm.
- Four rats were also prepared with 3 mL of saline administered intraperitoneally.
- Each rat was given 0.6 ⁇ g of buprenorphine intramuscularly after applying the adhesion inhibitor and closing the wound, and then awakened. Two weeks after the above surgery, the rats were euthanized and re-opened to evaluate adhesion.
- adhesions were evaluated by visual observation and scored according to the following adhesion score of 0 to 5, which is a 6-level scale. 0: no adhesion; 1: thin membrane-like adhesion; 2: multiple thin membrane-like adhesions; 3: thick adhesions with spots; 4: thick adhesions with surface attachment; 5: very thick adhesions with neovascularization or multiple surface attachments
- the abraded parts of the cecum and the abdominal wall parts with lacerations were collected and washed with saline.
- the collected tissues were immersed in 10% neutral buffered formalin (Fujifilm Wako Pure Chemical Industries, Ltd.) and fixed by leaving them at room temperature for more than 3 days.
- the fixed tissues were embedded in OCT compound (Sakura Finetech Japan Co., Ltd.) and frozen at -20°C.
- the tissues were then sliced to a thickness of 10-12 ⁇ m using a cryostat (Leica, "CM3050S”) and attached to APS-coated glass slides (Matsunami Glass Co., Ltd.).
- the tissues were immersed in 95% (v/v) ethanol (Fujifilm Wako Pure Chemical Industries, Ltd.) at 4°C for 10 minutes and dried at room temperature. Thereafter, the sections were immersed in running water for 2 minutes, Mayer's hematoxylin solution (Fujifilm Wako Pure Chemical Industries, Ltd.) for 10 minutes, running water for 15 minutes, 1% eosin Y solution (Fujifilm Wako Pure Chemical Industries, Ltd.) for 2 minutes, 70% (v/v) ethanol for 15 seconds, 99.5% ethanol for 15 seconds, xylene (Fujifilm Wako Pure Chemical Industries, Ltd.) for 1 minute, and xylene for 2 minutes at room temperature to perform hematoxylin-eosin staining.
- the stained tissue sections were mounted in mounting medium (Merck, "Entelaneu”) and bright field images were observed using a microscope (Keyence, "BZX710").
- Figure 4 is a box plot showing the adhesion score results for each adhesion prevention material. Specifically, for saline, the adhesion scores for four rats were 0, 1, 4, and 4, with an average adhesion score of 2.25. For the silk fibroin film (HMW) of Comparative Example 4, the adhesion scores for four rats were 2, 3, 5, and 0, with an average adhesion score of 2.50. For the silk fibroin film (LMW) of Example 4, the adhesion scores for four rats were 0, 0, 0, and 4, with an average adhesion score of 1.00. For Seprafilm, two of the six rats died within three days after implantation, and the adhesion scores for four rats were 0, 0, 5, and 0, with an average adhesion score of 1.25. In the case of Tenaleaf, one of the five rats died within three days of implantation, and the adhesion scores of three rats were 0, 3, 3, and 0, with an average adhesion score of 1.50.
- HMW silk fibroin film
- LMW silk fibroin film
- Seprafilm two of
- Figure 6 is a photograph showing the cecum and abdominal wall (adhesion score: 5) two weeks after implantation of the silk fibroin film of Comparative Example 4
- Figure 7 is a photograph showing the adhesion area.
- the silk fibroin film of Comparative Example 4 had a lower average adhesion score than the physiological saline solution used as a reference example, indicating that simply containing silk fibroin is not enough to achieve adhesion prevention effects.
- the silk fibroin film of Example 4 showed a better average adhesion score than the commercially available film-type adhesion prevention materials Seprafilm and Tenaleaf. Also, although the cause is unknown, some rats that received Seprafilm and Tenaleaf died within three days after transplantation, whereas no rats died after receiving the silk fibroin film of Example 4, suggesting that it is also safe.
- FIGs 8 and 9 are stained photographs showing the condition of the abdominal wall (AW) and cecum (C) two weeks after applying saline (Saline) of Comparative Example 1 and silk fibroin film (HMW) of Comparative Example 4 to the laceration wound, respectively. As shown in Figures 8 and 9, the abdominal wall and cecum had adhered to each other and were integrated.
- Figure 10 is a stained photograph showing the condition of the abdominal wall (AW) and cecum (C) two weeks after the silk fibroin film (LMW) of Example 4 was applied to the laceration. As shown in Figure 10, the abdominal wall and cecum were separated from each other, and no adhesions were observed.
- Figures 11 and 12 are stained photographs showing the condition of the abdominal wall (AW) and cecum (C) two weeks after the application of commercially available Seprafilm and Tenaleaf, respectively, to the laceration. As shown in Figures 11 and 12, even when the commercially available adhesion barrier was used, the abdominal wall and cecum remained separated from each other and no adhesions were observed.
- the silk fibroin film according to the present invention exhibited an adhesion prevention effect equal to or greater than that of commercially available film-type adhesion prevention materials.
- the silk fibroin film of Comparative Example 4 failed to exhibit an adhesion prevention effect.
- the evaluation results of the in vivo test confirmed that the silk fibroin film of the present invention exhibits adhesion prevention effects equal to or greater than those of commercially available film-type adhesion prevention materials, and was also confirmed to be decomposed and absorbed by the body within two weeks after implantation, demonstrating its usefulness as an adhesion prevention material.
- the silk fibroin film of the present invention can be used as an adhesion prevention material to prevent adhesion of any tissue or organ where adhesion may occur in various surgeries in the clinical fields of gastrointestinal surgery, cardiac surgery, orthopedic surgery, obstetrics and gynecology, etc. (particularly gastrointestinal surgery and obstetrics and gynecology).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Manufacture Of Macromolecular Shaped Articles (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
本願は、日本国で2023年8月29日に出願した特願2023-139250の優先権を主張するものであり、その全体を参照により本出願の一部をなすものとして引用する。 This application claims priority to Patent Application No. 2023-139250, filed in Japan on August 29, 2023, the entire contents of which are incorporated herein by reference as a part of this application.
本発明は、癒着防止材に用いられるシルクフィブロインフィルムおよびそれを含む癒着防止材に関する。 The present invention relates to a silk fibroin film for use in an anti-adhesion material and to an anti-adhesion material containing the same.
消化器外科、心臓外科、整形外科、産婦人科等の臨床分野では、外科手術後に、本来は離れているべき組織や臓器間で結合して離れなくなる癒着が生じてしまうことがある。癒着が生じることで、癒着剥離のために再手術を必要とする場合があり、多大な時間や労力を要することになり、さらには剥離の際に新たな損傷を引き起こすこともあり得る。また、腸閉塞や不妊症等の合併症を引き起こす場合もある。 In clinical fields such as gastrointestinal surgery, cardiac surgery, orthopedics, and obstetrics and gynecology, adhesions can form after surgery, bonding tissues and organs that should normally be separate and becoming inseparable. The formation of adhesions can necessitate a second surgery to remove the adhesions, which can take a lot of time and effort, and can even cause new damage during the removal process. It can also lead to complications such as intestinal obstruction and infertility.
組織や臓器間での癒着を防止するために様々な方法が検討されており、組織や臓器表面に適用することにより組織や臓器同士の接触を物理的に防ぐ癒着防止材が開発されている。癒着防止材はフィルム状やスプレー状等の形態の材料として開発されているが、消化器外科分野や産婦人科分野では、フィルム状の癒着防止材が臨床応用されている。例えば、フィルム状の癒着防止材としては、ヒアルロン酸およびカルボキシメチルセルロースを含有するセプラフィルム(登録商標)、ゼラチンを含有するテナリーフ(登録商標)等が挙げられる。しかしながら、これらの癒着防止材に含有されている成分に過敏症の既往歴のある患者に対しては使用できないため、臨床現場で使用できる選択肢を広げる必要がある。 Various methods have been investigated to prevent adhesion between tissues and organs, and anti-adhesion materials have been developed that physically prevent contact between tissues or organs by applying them to the surfaces of tissues or organs. Anti-adhesion materials have been developed in the form of films or sprays, and film-type anti-adhesion materials are used clinically in the fields of gastrointestinal surgery and obstetrics and gynecology. Examples of film-type anti-adhesion materials include Seprafilm (registered trademark), which contains hyaluronic acid and carboxymethylcellulose, and Tenaleaf (registered trademark), which contains gelatin. However, these anti-adhesion materials cannot be used on patients with a history of hypersensitivity to the components contained in them, so there is a need to expand the options available in clinical settings.
一方で、近年、シルクフィブロインは生体親和性に優れているため、生体材料として注目を集めている。例えば、特許文献1(特表2016-517443号公報)には、ある範囲の分子量を有する絹フィブロイン断片の集団を含む低分子量絹フィブロイン組成物であって、前記集団中の前記絹フィブロイン断片の総数の15%以下が、200kDaを超える分子量を有し、前記集団中の前記絹フィブロイン断片の前記総数の少なくとも50%が、指定範囲内の分子量を有し、前記指定範囲が、約3.5kDa以上の下限と約120kDa以下の上限との間であることを特徴とする低分子量絹フィブロイン組成物が開示されており、フィルム形態で使用できること、および医療用途で使用できることが記載されている。 On the other hand, in recent years, silk fibroin has attracted attention as a biomaterial due to its excellent biocompatibility. For example, Patent Document 1 (JP Patent Publication No. 2016-517443) discloses a low molecular weight silk fibroin composition containing a population of silk fibroin fragments having a certain range of molecular weights, wherein 15% or less of the total number of the silk fibroin fragments in the population have a molecular weight exceeding 200 kDa, and at least 50% of the total number of the silk fibroin fragments in the population have a molecular weight within a specified range, the specified range being between a lower limit of about 3.5 kDa or more and an upper limit of about 120 kDa or less, and the composition is described as being usable in the form of a film and for medical purposes.
また、特許文献2(米国特許第9427499号明細書)には、第1の表面の少なくとも一部が、約75~約750μgPEG/cm2シルクフィブロインマトリックスの密度でポリ(エチレングリコール)(PEG)で選択的に修飾されたシルクフィブロインマトリックスが開示されており、癒着防止材に使用できることが記載されている。 Furthermore, Patent Document 2 (U.S. Pat. No. 9,427,499) discloses a silk fibroin matrix in which at least a portion of a first surface is selectively modified with poly(ethylene glycol) (PEG) at a density of about 75 to about 750 μg PEG/ cm2 silk fibroin matrix, and describes that the silk fibroin matrix can be used as an adhesion barrier.
しかしながら、特許文献1には、低分子量化させた絹フィブロインは水溶性を高くすることができることが記載されているものの、低分子量絹フィブロイン組成物を癒着防止材として使用することについては記載されていない。 However, although Patent Document 1 describes that low molecular weight silk fibroin can be made more water soluble, it does not describe the use of low molecular weight silk fibroin compositions as adhesion prevention materials.
また、特許文献2には、シルクフィブロインマトリックスの表面をPEGで改質することによって、間葉系幹細胞および線維芽細胞のそれぞれについて、接着性および増殖促進性を抑制することが記載されているが、これらの抑制に寄与しているのは表面のPEGであり、シルクフィブロイン自体の構造による効果を見出しているものではない。また、invivoでの癒着防止効果を評価してはいない。 Patent Document 2 also describes that modifying the surface of a silk fibroin matrix with PEG suppresses the adhesiveness and proliferation-promoting properties of mesenchymal stem cells and fibroblasts, respectively, but it is the PEG on the surface that contributes to these inhibitions, and the paper does not find any effect due to the structure of the silk fibroin itself. Furthermore, the paper did not evaluate the adhesion prevention effect in vivo.
したがって、本発明の目的は、癒着防止材としての用途に適したシルクフィブロインフィルムを提供することにある。 The object of the present invention is therefore to provide a silk fibroin film suitable for use as an adhesion prevention material.
本発明の発明者らは、上記目的を達成するために鋭意検討した結果、フィルム表面が短時間で水に溶解するシルクフィブロインフィルムは、癒着防止効果に優れることを見出し、本発明の完成に至った。 As a result of extensive research into achieving the above objective, the inventors of the present invention discovered that a silk fibroin film, the surface of which dissolves in water in a short period of time, has excellent adhesion prevention effects, leading to the completion of the present invention.
すなわち、本発明は、以下の態様で構成されうる。
〔態様1〕
癒着防止材用のシルクフィブロインフィルムであって、水に浮かべてから24時間以内(好ましくは12時間以内、より好ましくは1時間以内、さらに好ましくは10分以内)に少なくともシルクフィブロインのフィルム表面が水に溶解する、シルクフィブロインフィルム。
〔態様2〕
態様1に記載のシルクフィブロインフィルムであって、フィルム表面の水の接触角の測定において、フィルム表面に5μLの超純水の水滴を滴下してから5秒後までの接触角変化が-5°/sec以下(好ましくは-20~-5°/sec、より好ましくは-15~-5°/sec、特に-10~-5°/sec)である、シルクフィブロインフィルム。
〔態様3〕
フィルム表面の水の接触角の測定において、フィルム表面に5μLの超純水の水滴を滴下してから5秒後までの接触角変化が-5°/sec以下(好ましくは-20~-5°/sec、より好ましくは-15~-5°/sec、特に-10~-5°/sec)である、シルクフィブロインフィルム。
〔態様4〕
態様1~3のいずれか一態様に記載のシルクフィブロインフィルムであって、水に浸漬させてから25℃で24時間インキュベートした後のフィルムの水溶解率が50%以上(好ましくは70%以上、より好ましくは80%以上、さらに好ましくは90%以上)である、シルクフィブロインフィルム。
〔態様5〕
態様1~4のいずれか一態様に記載のシルクフィブロインフィルムであって、水に浸漬させてから25℃で1時間インキュベートした後のフィルムの水溶解率が100%以下(好ましくは99%以下、より好ましくは98%以下)である、シルクフィブロインフィルム。
〔態様6〕
態様1~5のいずれか一態様に記載のシルクフィブロインフィルムであって、シルクフィブロインの重量平均分子量が150kDa以下(好ましくは120kDa以下、より好ましくは100kDa以下、さらに好ましくは90kDa以下)である、シルクフィブロインフィルム。
〔態様7〕
態様1~6のいずれか一態様に記載のシルクフィブロインフィルムであって、フィルム表面に存在するシルクフィブロインがポリエチレングリコールにより修飾されていないシルクフィブロインである、シルクフィブロインフィルム。
〔態様8〕
態様1~7のいずれか一態様に記載のシルクフィブロインフィルムであって、含水率が30%以下(好ましくは1~30%、より好ましくは3~20%、さらに好ましくは5~15%)である、シルクフィブロインフィルム。
〔態様9〕
重量平均分子量が40~150kDa(好ましくは50~120kDa、より好ましくは55~100kDa)であるとともに、分子量分布(PDI)が1~10(好ましくは1.2~9、より好ましくは1.5~8)であるシルクフィブロインを含む、シルクフィブロインフィルム。
〔態様10〕
態様1~7のいずれか一態様に記載のシルクフィブロインフィルムを含む癒着防止材。
〔態様11〕
癒着防止材用のシルクフィブロインフィルムの製造方法であって、精練されたシルクフィブロインを溶媒に溶解させて、アルカリ処理剤と反応させるアルカリ処理工程と、アルカリ処理されたシルクフィブロインを製膜する工程とを含む、シルクフィブロインフィルムの製造方法。
〔態様12〕
態様11に記載の製造方法であって、アルカリ処理されたシルクフィブロインの重量平均分子量が150kDa以下(好ましくは120kDa以下、より好ましくは100kDa以下、さらに好ましくは80kDa以下)である、シルクフィブロインフィルムの製造方法。
〔態様13〕
態様10に記載の癒着防止材を用いた癒着防止方法であって、前記癒着防止材を、術後の臓器の離断面および術後の臓器の周囲組織表面の少なくともいずれかに適用する工程を含む、癒着防止方法。
That is, the present invention can be configured in the following manner.
[Aspect 1]
The silk fibroin film is an anti-adhesion material, in which at least the surface of the silk fibroin film dissolves in water within 24 hours (preferably within 12 hours, more preferably within 1 hour, and even more preferably within 10 minutes) after being floated on water.
[Aspect 2]
A silk fibroin film according to embodiment 1, wherein, in a measurement of the contact angle of water on the film surface, the change in contact angle from when a 5 μL droplet of ultrapure water is dropped on the film surface until 5 seconds later is −5°/sec or less (preferably −20 to −5°/sec, more preferably −15 to −5°/sec, particularly preferably −10 to −5°/sec).
[Aspect 3]
A silk fibroin film, in which, in measurement of the contact angle of water on the film surface, the change in contact angle from when a 5 μL droplet of ultrapure water is dropped on the film surface until 5 seconds later is −5°/sec or less (preferably −20 to −5°/sec, more preferably −15 to −5°/sec, particularly preferably −10 to −5°/sec).
[Aspect 4]
The silk fibroin film according to any one of aspects 1 to 3, wherein the water solubility of the film after immersion in water and incubation at 25° C. for 24 hours is 50% or more (preferably 70% or more, more preferably 80% or more, and even more preferably 90% or more).
[Aspect 5]
The silk fibroin film according to any one of aspects 1 to 4, wherein the water solubility of the film after immersion in water and incubation at 25° C. for 1 hour is 100% or less (preferably 99% or less, more preferably 98% or less).
[Aspect 6]
A silk fibroin film according to any one of aspects 1 to 5, wherein the weight-average molecular weight of the silk fibroin is 150 kDa or less (preferably 120 kDa or less, more preferably 100 kDa or less, and even more preferably 90 kDa or less).
[Aspect 7]
7. The silk fibroin film according to any one of claims 1 to 6, wherein the silk fibroin present on the film surface is silk fibroin that is not modified with polyethylene glycol.
[Aspect 8]
A silk fibroin film according to any one of aspects 1 to 7, wherein the silk fibroin film has a moisture content of 30% or less (preferably 1 to 30%, more preferably 3 to 20%, and even more preferably 5 to 15%).
Aspect 9
A silk fibroin film comprising silk fibroin having a weight average molecular weight of 40 to 150 kDa (preferably 50 to 120 kDa, more preferably 55 to 100 kDa) and a molecular weight distribution (PDI) of 1 to 10 (preferably 1.2 to 9, more preferably 1.5 to 8).
[Aspect 10]
An adhesion preventing material comprising the silk fibroin film according to any one of aspects 1 to 7.
[Aspect 11]
The present invention relates to a method for producing a silk fibroin film for use as an anti-adhesion material, the method comprising the steps of: dissolving refined silk fibroin in a solvent and reacting the resulting solution with an alkali treating agent; and forming a film from the alkali-treated silk fibroin.
[Aspect 12]
A method for producing a silk fibroin film according to aspect 11, wherein the weight-average molecular weight of the alkali-treated silk fibroin is 150 kDa or less (preferably 120 kDa or less, more preferably 100 kDa or less, and even more preferably 80 kDa or less).
[Aspect 13]
A method for preventing adhesions using the adhesion preventing material according to
本明細書で使用される場合、単数形、「a」、「an」及び「the」は、内容が明確にそうでないことを示さない限り、「at least one」を含む複数形を含むことを意図している。本明細書で使用される場合、用語「および/または」、「少なくとも1」、および「1以上」は、関連する列挙された項目の任意の及び全ての組合せを含む。 As used herein, the singular forms "a," "an," and "the" are intended to include the plural forms "at least one," unless the content clearly dictates otherwise. As used herein, the terms "and/or," "at least one," and "one or more" include any and all combinations of the associated listed items.
また、「約」と称する場合、当該数値に対する±10%の範囲、好ましくは±5%の範囲が含まれてもよい。 Furthermore, when referring to "about," the range may include ±10% of the numerical value, and preferably ±5%.
なお、請求の範囲および/または明細書および/または図面に開示された少なくとも2つの構成要素のどのような組み合わせも、本発明に含まれる。特に、請求の範囲に記載された請求項の2つ以上のどのような組み合わせも本発明に含まれる。 It should be noted that any combination of at least two components disclosed in the claims and/or the specification and/or the drawings is included in the present invention. In particular, any combination of two or more of the claims described in the claims is included in the present invention.
本発明のシルクフィブロインフィルムは、術後の組織や臓器間の癒着を防止することができ、また、従来のフィルム状の癒着防止材とは異なる成分を含有するため、患者の過敏症に合わせて癒着防止材の選択肢として使用することができる。 The silk fibroin film of the present invention can prevent adhesions between tissues and organs after surgery, and because it contains ingredients different from conventional film-type adhesion barriers, it can be used as an adhesion barrier of choice depending on the patient's sensitivity.
(シルクフィブロインフィルム)
シルクフィブロインフィルムは、水に浮かべてから24時間以内に少なくともシルクフィブロインのフィルム表面が水に溶解する。本明細書において、フィルム表面が水に溶解するとは、後述の実施例に記載した方法により観察され、一辺1cmの正方形のフィルム表面に油性ペン(黒色)で描かれた正方形およびその対角線の6本の直線(線幅1mm)が全て分断されることにより確認できる。すなわち、フィルムの第1の面に油性ペンの線を描き、第1の面を上、第2の面を下にしてフィルムを水に浮かべた場合、フィルム表面(第1の面)が水に溶解することにより、第1の面に描いた油性ペンの6本の直線のそれぞれがフィルムから剥がれるとともに、互いから離れ、各直線が亀裂により分断していく。そのため、フィルム表面に油性ペンの直線を描いたフィルムを水に浮かべた後、油性ペンの直線がフィルム表面とともに剥がれて、最終的に6本の直線が全て分断することを確認することにより、フィルム表面の水溶性を評価することができる。フィルムを水に浮かべる際にフィルム上側の面が溶解することを確認することにより、フィルム下側の面(第2の面)についても、フィルム表面が溶解するとみなすことができる。なお、24時間以内に少なくともフィルム表面が水に溶解すればよく、フィルム表面以外の部分は溶解してもよいし、溶解していなくてもよい。したがって、24時間以内にフィルム全体が水に溶解してもよい。本発明では、シルクフィブロインフィルムのフィルム表面の水溶性が高いことにより、フィルム表面と細胞やフィブリン等と長時間の接触状態を防止でき、細胞やフィブリン等の接着が阻害されるためか、また、接着、吸着しようとした細胞やフィブリン等がフィルム表面と共に剥がれるためか、癒着防止効果を発揮できる。フィルム表面が水に溶解する時間としては、水に浮かべてから12時間以内が好ましく、より好ましくは1時間以内、さらに好ましくは10分以内であってもよい。また、フィルム表面が水に溶解する時間の下限は特に限定されないが、例えば、1秒以上であってもよく、貼り直しを行いやすい観点から、好ましくは30秒以上、より好ましくは50秒以上、特に好ましくは100秒以上であってもよい。
(Silk fibroin film)
The silk fibroin film dissolves in water at least at the surface of the silk fibroin within 24 hours after floating on water. In this specification, the dissolution of the film surface in water can be confirmed by observing the method described in the examples below, and by confirming that the square drawn with an oil pen (black) on the surface of a square film with sides of 1 cm and the six straight lines (line width 1 mm) of the square drawn with an oil pen are all broken. That is, when a line is drawn with an oil pen on the first surface of the film and the film is floated on water with the first surface facing up and the second surface facing down, the film surface (first surface) dissolves in water, and each of the six straight lines drawn with an oil pen on the first surface peels off from the film and separates from each other, and each straight line is broken by cracks. Therefore, the water solubility of the film surface can be evaluated by confirming that the straight lines drawn with an oil pen peel off together with the film surface after the film is floated on water, and finally all six straight lines are broken. By confirming that the upper surface of the film dissolves when the film is floated on water, the film surface of the lower surface (second surface) of the film can also be considered to dissolve. It should be noted that at least the film surface needs to dissolve in water within 24 hours, and the portions other than the film surface may or may not dissolve. Therefore, the entire film may dissolve in water within 24 hours. In the present invention, the high water solubility of the film surface of the silk fibroin film can prevent the film surface from being in contact with cells, fibrin, etc. for a long time, and the adhesion of cells, fibrin, etc. is inhibited, or the cells, fibrin, etc. that are intended to be adhered or adsorbed are peeled off together with the film surface, so that the adhesion prevention effect can be exerted. The time for which the film surface dissolves in water is preferably within 12 hours after floating on water, more preferably within 1 hour, and even more preferably within 10 minutes. In addition, the lower limit of the time for which the film surface dissolves in water is not particularly limited, but may be, for example, 1 second or more, and from the viewpoint of easy re-application, it may be preferably 30 seconds or more, more preferably 50 seconds or more, and particularly preferably 100 seconds or more.
シルクフィブロインフィルムは、癒着防止材としての分解吸収による効果の観点から、水に浸漬させてから25℃で24時間インキュベートした後のフィルムの水溶解率(以下、単に、24時間後の水溶解率と称する場合がある)が50%以上であってもよく、好ましくは70%以上、より好ましくは80%以上、さらに好ましくは90%以上であってもよい。なお、水に浸漬させてから24時間後の水溶解率の上限値は特に限定されず、100%以下であってもよい。なお、24時間後の水溶解率は、後述する実施例に記載された方法により測定された値である。 From the viewpoint of the effect of decomposition and absorption as an adhesion prevention material, the water solubility of the silk fibroin film after immersion in water and incubation at 25°C for 24 hours (hereinafter, sometimes simply referred to as the water solubility after 24 hours) may be 50% or more, preferably 70% or more, more preferably 80% or more, and even more preferably 90% or more. The upper limit of the water solubility after 24 hours after immersion in water is not particularly limited, and may be 100% or less. The water solubility after 24 hours is a value measured by the method described in the examples below.
また、シルクフィブロインフィルムは、癒着防止材としての物理的バリア機能の維持の観点から、水に浸漬させてから25℃で1時間インキュベートした後のフィルムの水溶解率(以下、単に、1時間後の水溶解率と称する場合がある)が100%以下であってもよく、好ましくは99%以下であってもよく、より好ましくは98%以下であってもよい。なお、水に浸漬させてから1時間後の水溶解率の下限値は特に限定されないが、例えば、癒着防止材としての分解吸収による効果の観点から、45%以上であってもよく、好ましくは55%以上、より好ましくは65%以上、さらに好ましくは75%以上であってもよい。 Furthermore, from the viewpoint of maintaining the physical barrier function as an adhesion prevention material, the water solubility of the silk fibroin film after immersion in water and incubation at 25°C for 1 hour (hereinafter, may be simply referred to as the water solubility after 1 hour) may be 100% or less, preferably 99% or less, and more preferably 98% or less. The lower limit of the water solubility after immersion in water for 1 hour is not particularly limited, but from the viewpoint of the effect of decomposition and absorption as an adhesion prevention material, for example, it may be 45% or more, preferably 55% or more, more preferably 65% or more, and even more preferably 75% or more.
シルクフィブロインフィルムは、フィルム表面の水の接触角の測定において、フィルム表面に5μLの超純水の水滴を滴下してから5秒後までの接触角変化が-5°/sec以下であってもよい。シルクフィブロインフィルムは、フィルム表面が水溶性を有しているため、フィルム表面に水滴を滴下すると、フィルム表面が水滴に溶解することにより接触角が変化していくが、水の接触角が短時間でよりマイナス側へ(絶対値としては大きく)変化することが好ましい。接触角変化は、好ましくは-20~-5°/sec、より好ましくは-15~-5°/sec、特に-10~-5°/secであってもよい。シルクフィブロインフィルムの水の接触角変化は、後述の実施例に記載した方法により測定される値である。図3に後述の実施例4のシルクフィブロインフィルムの水の接触角の時間変化のプロットデータを示しているが、フィルム表面に水滴を滴下してから初期の段階では、水の接触角が小さくなっており、その後、水の接触角は略一定になっている。フィルム表面に水滴を滴下した時を0秒として、初期の段階である0~5秒におけるプロットデータを最小二乗法により直線近似し、得られた近似直線(図3の直線)の傾きを水の接触角変化とする。 In the measurement of the contact angle of water on the surface of the silk fibroin film, the change in the contact angle from dropping a 5 μL drop of ultrapure water on the film surface until 5 seconds later may be -5°/sec or less. Since the surface of the silk fibroin film is water-soluble, when a drop of water is dropped on the film surface, the film surface dissolves in the drop of water, causing the contact angle to change. It is preferable that the contact angle of water changes more negatively (larger in absolute value) in a short time. The change in the contact angle may be preferably -20 to -5°/sec, more preferably -15 to -5°/sec, and particularly -10 to -5°/sec. The change in the contact angle of water on the silk fibroin film is a value measured by the method described in the examples below. Figure 3 shows plot data of the change in the contact angle of water over time for the silk fibroin film of Example 4 described below. In the early stage after dropping a drop of water on the film surface, the contact angle of water is small, and thereafter, the contact angle of water is approximately constant. The time when a water droplet is dropped onto the film surface is set to 0 seconds, and the plot data from 0 to 5 seconds, which is the initial stage, is linearly approximated using the least squares method, and the slope of the resulting approximate line (the line in Figure 3) is the change in the contact angle of water.
シルクフィブロインフィルムは、フィルム表面が水溶性を有しているが、必ずしも水と接触した直後から高いぬれ性を示す必要はない。例えば、フィルム表面に水滴を滴下した直後は水の接触角が大きくても、水溶性を有していることで上述の接触角変化を有していてもよい。例えば、シルクフィブロインフィルムは、フィルム表面の水の接触角の測定において、フィルム表面に水滴を滴下した時(0秒)の接触角が50~90°であってもよく、好ましくは55~85°、より好ましくは60~80°であってもよい。シルクフィブロインフィルムの0秒での水の接触角は、後述の実施例に記載した方法により測定される値であり、フィルム表面に水滴を滴下した時を0秒として、0~5秒における接触角の測定データを最小二乗法により直線近似し、得られた直線の切片を示す。 The silk fibroin film has a water-soluble film surface, but does not necessarily have to show high wettability immediately after contact with water. For example, the contact angle of water may be large immediately after a water droplet is dropped on the film surface, but the film may have the above-mentioned contact angle change due to its water-solubility. For example, in measuring the contact angle of water on the surface of a silk fibroin film, the contact angle when a water droplet is dropped on the film surface (0 seconds) may be 50 to 90°, preferably 55 to 85°, and more preferably 60 to 80°. The water contact angle of a silk fibroin film at 0 seconds is a value measured by the method described in the Examples below. The time when a water droplet is dropped on the film surface is set to 0 seconds, and the measurement data of the contact angle from 0 to 5 seconds is linearly approximated by the least squares method, and the intercept of the obtained line is shown.
シルクフィブロインフィルムは、シルクフィブロインを含む。シルクフィブロインは、主にグリシン、アラニン、セリン、チロシンを含み、分子が規則正しく並ぶ結晶性部分と、ランダムに配列する非晶性部分とで構成され、通常、繊維状タンパク質の一種として知られている。シルクフィブロインは、このような構成を有していればその原料は特に限定されず、例えば、後述の絹原料からシルクフィブロインを得ることができる。また、シルクフィブロインは、本発明の効果を阻害しない範囲で、化学的に修飾されていてもよい。
本明細書において、単に「シルクフィブロイン」と記載する場合には、その定義には化学修飾されたシルクフィブロインも包含される。ただし、フィルム表面に存在するシルクフィブロインがポリエチレングリコール(PEG)により修飾されていないシルクフィブロインであってもよい。
The silk fibroin film contains silk fibroin. Silk fibroin mainly contains glycine, alanine, serine, and tyrosine, and is composed of a crystalline portion in which the molecules are regularly arranged and an amorphous portion in which the molecules are randomly arranged, and is generally known as a type of fibrous protein. As long as the silk fibroin has such a structure, the raw material is not particularly limited, and silk fibroin can be obtained from, for example, a silk raw material described later. In addition, silk fibroin may be chemically modified within a range that does not impair the effects of the present invention.
In this specification, when the term "silk fibroin" is used, the definition includes chemically modified silk fibroin, although the silk fibroin present on the film surface may be silk fibroin that is not modified with polyethylene glycol (PEG).
シルクフィブロインフィルムは、癒着防止材としてシルクフィブロインの特性を発揮する観点から、未修飾シルクフィブロインを含むことが好ましい。本明細書において、未修飾シルクフィブロインとは、シルクフィブロインに官能基や架橋結合等を導入する反応やグラフト化反応が行われておらず、シルクフィブロインを構成するアミノ酸残基の側鎖が化学修飾されていないシルクフィブロインを意味する。 The silk fibroin film preferably contains unmodified silk fibroin in order to utilize the properties of silk fibroin as an adhesion prevention material. In this specification, unmodified silk fibroin means silk fibroin that has not been subjected to a reaction to introduce functional groups or crosslinking or a grafting reaction, and the side chains of the amino acid residues that constitute the silk fibroin have not been chemically modified.
シルクフィブロインは、フィルム表面の水溶性向上の観点から、重量平均分子量(Mw)が150kDa以下(例えば、10~150kDa)であってもよく、好ましくは120kDa以下、より好ましくは100kDa以下、さらに好ましくは90kDa以下であってもよい。重量平均分子量の下限値は特に限定されないが、例えば、10kDa以上、好ましくは40kDa以上、より好ましくは50kDa以上であってもよい。なお、シルクフィブロインの重量平均分子量は、後述の実施例に記載の方法によって測定される値である。 From the viewpoint of improving the water solubility of the film surface, the silk fibroin may have a weight average molecular weight (Mw) of 150 kDa or less (e.g., 10 to 150 kDa), preferably 120 kDa or less, more preferably 100 kDa or less, and even more preferably 90 kDa or less. There is no particular limit to the lower limit of the weight average molecular weight, but it may be, for example, 10 kDa or more, preferably 40 kDa or more, and more preferably 50 kDa or more. The weight average molecular weight of silk fibroin is a value measured by the method described in the Examples below.
また、シルクフィブロインは、数平均分子量(Mn)が80kDa以下(例えば、1~70kDa)であってもよく、好ましくは60kDa以下、より好ましくは50kDa以下、さらに好ましくは40kDa以下、さらにより好ましくは30kDa以下であってもよい。数平均分子量の下限値は特に限定されないが、例えば、1kDa以上、好ましくは5kDa以上であってもよい。なお、シルクフィブロインの数平均分子量は、後述の実施例に記載の方法によって測定される値である。 The number average molecular weight (Mn) of silk fibroin may be 80 kDa or less (e.g., 1 to 70 kDa), preferably 60 kDa or less, more preferably 50 kDa or less, even more preferably 40 kDa or less, and even more preferably 30 kDa or less. There is no particular limit to the lower limit of the number average molecular weight, but it may be, for example, 1 kDa or more, preferably 5 kDa or more. The number average molecular weight of silk fibroin is a value measured by the method described in the Examples below.
シルクフィブロインの分子量分布は、1~10(例えば1~4)であってもよく、好ましくは1.2~9(例えば1.2~3.8)、より好ましくは1.5~8(例えば、1.5~3.5)、さらに好ましくは2~6、特に好ましくは3~5であってもよい。なお、分子量分布は、重量平均分子量(Mw)の値を数平均分子量(Mn)の値で除することで求められる多分散度(PDI)を示す。 The molecular weight distribution of silk fibroin may be 1 to 10 (e.g., 1 to 4), preferably 1.2 to 9 (e.g., 1.2 to 3.8), more preferably 1.5 to 8 (e.g., 1.5 to 3.5), even more preferably 2 to 6, and particularly preferably 3 to 5. The molecular weight distribution indicates the polydispersity index (PDI) calculated by dividing the weight average molecular weight (Mw) by the number average molecular weight (Mn).
シルクフィブロインは、ピークトップ分子量(Mp)が250kDa以下(例えば、10~250kDa)であってもよく、好ましくは150kDa以下、より好ましくは100kDa以下、さらにより好ましくは80kDa以下、特に好ましくは60kDa以下、さらに好ましくは50kDa以下であってもよい。ピークトップ分子量の下限値は特に限定されないが、例えば、5kDa以上、好ましくは10kDa以上であってもよい。なお、ピークトップ分子量とは、クロマトグラムで検出されたピークトップの位置に相当する分子量を指し、後述の実施例に記載の方法によって測定される値である。 The peak top molecular weight (Mp) of silk fibroin may be 250 kDa or less (e.g., 10 to 250 kDa), preferably 150 kDa or less, more preferably 100 kDa or less, even more preferably 80 kDa or less, particularly preferably 60 kDa or less, and even more preferably 50 kDa or less. The lower limit of the peak top molecular weight is not particularly limited, but may be, for example, 5 kDa or more, preferably 10 kDa or more. The peak top molecular weight refers to the molecular weight corresponding to the position of the peak top detected in a chromatogram, and is a value measured by the method described in the Examples below.
好ましいシルクフィブロインフィルムには、例えば、重量平均分子量が40~150kDa、好ましくは50~120kDa、より好ましくは55~100kDaであるとともに、分子量分布(PDI)が1~10(例えば1~4)であってもよく、好ましくは1.2~9(例えば1.2~3.8)、より好ましくは1.5~8(例えば、1.5~3.5)であるシルクフィブロインを含む、シルクフィブロインフィルムが包含される。また、シルクフィブロインフィルムは、上述の各種特徴を備えていてもよい。 Preferred silk fibroin films include silk fibroin films containing silk fibroin having a weight average molecular weight of 40 to 150 kDa, preferably 50 to 120 kDa, more preferably 55 to 100 kDa, and a molecular weight distribution (PDI) of 1 to 10 (e.g., 1 to 4), preferably 1.2 to 9 (e.g., 1.2 to 3.8), more preferably 1.5 to 8 (e.g., 1.5 to 3.5). The silk fibroin film may also have the various characteristics described above.
シルクフィブロインフィルムは、含水率が30%以下であってもよく、好ましくは1~30%、より好ましくは3~20%、さらに好ましくは5~15%であってもよい。シルクフィブロインフィルムの含水率は、シルクフィブロインフィルムに含有される水の重量割合(シルクフィブロインフィルムの重量に対する水の含有重量の割合)であり、後述の実施例に記載の方法によって測定される値である。 The moisture content of the silk fibroin film may be 30% or less, preferably 1-30%, more preferably 3-20%, and even more preferably 5-15%. The moisture content of the silk fibroin film is the weight ratio of water contained in the silk fibroin film (the ratio of the weight of water contained to the weight of the silk fibroin film), and is a value measured by the method described in the examples below.
シルクフィブロインフィルムは、シルクフィブロインおよび水以外の成分(例えば着色剤などの添加物)を含有していてもよいが、シルクフィブロインの含有率は、固形分重量に対して90%以上であってもよく、好ましくは95%以上、より好ましくは98%以上、さらに好ましくは99.9%以上であってもよい。 The silk fibroin film may contain components other than silk fibroin and water (e.g. additives such as colorants), but the silk fibroin content may be 90% or more by weight of solid matter, preferably 95% or more, more preferably 98% or more, and even more preferably 99.9% or more.
例えば、シルクフィブロインフィルムに着色料が含まれる場合、医療従事者が、臓器表面等における癒着防止材を適用した領域を目視で確認することが容易になり、有利な場合がある。 For example, if the silk fibroin film contains a coloring agent, this can be advantageous as it makes it easier for medical professionals to visually confirm the areas on the surface of organs, etc. where the adhesion prevention material has been applied.
シルクフィブロインフィルムは、癒着防止材の使用臨床分野や使用箇所等に応じて厚さを適宜選択することができ、例えば、1μm~5mmの広い範囲から選択可能であるが、消化器外科や産婦人科分野に使用することを考慮すると、シルクフィブロインフィルムの厚さは、例えば1μm~1mm、好ましくは5~200μm(例えば7~180μm)、より好ましくは10~150μmであってもよい。 The thickness of the silk fibroin film can be appropriately selected depending on the clinical field and location of use of the adhesion prevention material, and can be selected from a wide range, for example, from 1 μm to 5 mm. However, when considering use in the fields of gastrointestinal surgery and obstetrics and gynecology, the thickness of the silk fibroin film may be, for example, 1 μm to 1 mm, preferably 5 to 200 μm (e.g., 7 to 180 μm), and more preferably 10 to 150 μm.
シルクフィブロインフィルムは、突刺し強度が0.01N以上(例えば、0.01~5N)であってもよく、好ましくは0.05N以上、より好ましくは0.1N以上であってもよい。突刺し強度が上記の範囲内にあると、癒着防止材として扱いやすい。シルクフィブロインフィルムの突刺し強度の上限は特に限定されないが、例えば、5N以下であってもよい。シルクフィブロインフィルムの突刺し強度は、後述の実施例に記載の方法によって測定される値である。 The silk fibroin film may have a puncture strength of 0.01 N or more (e.g., 0.01 to 5 N), preferably 0.05 N or more, and more preferably 0.1 N or more. If the puncture strength is within the above range, it is easy to handle as an adhesion prevention material. There is no particular upper limit to the puncture strength of the silk fibroin film, but it may be, for example, 5 N or less. The puncture strength of the silk fibroin film is a value measured by the method described in the Examples below.
(癒着防止材)
シルクフィブロインフィルムは、これを含む癒着防止材として用いられる。本明細書において、「癒着防止材」とは、手術後の炎症等によって、本来は離れているべき組織表面や臓器表面が他の組織表面や臓器表面と結合して離れなくなる現象である「癒着」を抑制することを目的として、癒着が生じる虞のある、外傷による臓器または組織の損傷部位、術後の臓器の離断面および術後の臓器の周囲組織表面等に適用する生体材料をいう。
(Anti-adhesion material)
Silk fibroin films are used as adhesion inhibitors, including the silk fibroin film. In this specification, the term "adhesion inhibitor" refers to a biomaterial that is applied to sites of organ or tissue damage caused by trauma, dissected surfaces of organs after surgery, and tissue surfaces surrounding organs after surgery, where adhesions may occur, for the purpose of suppressing "adhesion," a phenomenon in which tissue surfaces or organ surfaces that should be separated from each other become bonded to other tissue surfaces or organ surfaces and cannot be separated due to inflammation after surgery or the like.
本明細書において「外傷」とは、外力(機械的、物理的、化学的)により生じた臓器または組織の損傷をいう。 In this specification, "trauma" refers to damage to organs or tissues caused by external forces (mechanical, physical, or chemical).
本明細書において「臓器」とは、独自の構造をもち、それぞれが特定の機能を有する解剖学的単位である体内器官を意味し、例えば、脳、心臓、食道、胃、膀胱、小腸、大腸、肝臓、腎臓、膵臓、脾臓、子宮などが挙げられる。 In this specification, "organ" refers to an internal organ, which is an anatomical unit with its own structure and specific function, such as the brain, heart, esophagus, stomach, bladder, small intestine, large intestine, liver, kidneys, pancreas, spleen, uterus, etc.
本明細書において「組織」とは、互いに関連する細胞や細胞の産生物質が合体して一定の機能を成す単位をいい、皮膚、筋肉、腱、骨、関節、靱帯、血管、膵島、角膜などが挙げられる。 In this specification, "tissue" refers to a unit that performs a certain function by combining related cells or substances produced by cells, and examples of such tissue include skin, muscle, tendon, bone, joint, ligament, blood vessel, pancreatic islet, and cornea.
本明細書において、「離断面」とは、外科手術等により組織や臓器の一部を切除または剥離することによって体内に晒されることとなった表面をいう。 In this specification, the term "dissected surface" refers to the surface that is exposed to the inside of the body after part of a tissue or organ is removed or peeled off during surgery or other procedures.
癒着防止材は、消化器外科、心臓外科、整形外科、産婦人科等の臨床分野における手術において、癒着が生じ得るあらゆる組織や臓器の癒着防止のために用いることができ、特に消化器外科および産婦人科における手術において好適に用いることができる。例えば、腸や腹膜の損傷部位、子宮や付属器の損傷部位等に貼付することにより用いることができる。また、ヒトの手術だけではなく、ペットなどの動物(非ヒト)の手術においても利用することができる。例えば、非ヒト動物としては、非ヒト哺乳動物が挙げられ、非ヒト哺乳動物としては、例えば類人猿、その他霊長類、マウス、ラット、ハムスター、モルモット、ウマ、ウシ、ブタ、ヒツジ、ヤギ、イヌ、ネコ、ウサギ等が挙げられる。なお、本明細書において、癒着防止は、癒着の発生を完全に防ぐことだけではなく、癒着の程度や範囲、頻度を軽減することも含む。 The adhesion prevention material can be used to prevent adhesion of any tissue or organ where adhesion may occur in surgery in clinical fields such as gastrointestinal surgery, cardiac surgery, orthopedics, and obstetrics and gynecology, and is particularly suitable for use in surgery in gastrointestinal surgery and obstetrics and gynecology. For example, it can be used by applying it to damaged areas of the intestine or peritoneum, or damaged areas of the uterus or appendages. It can also be used not only in human surgery, but also in surgery on animals (non-humans) such as pets. For example, non-human animals include non-human mammals, such as apes, other primates, mice, rats, hamsters, guinea pigs, horses, cows, pigs, sheep, goats, dogs, cats, and rabbits. In this specification, adhesion prevention does not only mean completely preventing the occurrence of adhesions, but also includes reducing the degree, range, and frequency of adhesions.
癒着防止材は、実質的に上記シルクフィブロインフィルムのみからなるものであってもよく、また、癒着防止材は、フィルムの形状維持に必要な支持体を含む積層体であってもよい。 The anti-adhesion material may consist essentially of the silk fibroin film, or it may be a laminate that includes a support necessary for maintaining the shape of the film.
癒着防止材は、好ましくは、開腹手術などの外科手術の仕上げ工程で、術後の臓器または組織の離断面および術後の臓器の周囲組織表面等に貼付されるものであってもよい。 The adhesion prevention material may be preferably applied to the dissected surface of an organ or tissue after surgery and to the surface of tissue surrounding the organ after surgery during the finishing process of a surgical procedure such as an abdominal surgery.
(シルクフィブロインフィルムの製造方法)
シルクフィブロインフィルムの製造方法は、精練されたシルクフィブロインを溶媒に溶解させて、アルカリ処理剤と反応させるアルカリ処理工程と、アルカリ処理されたシルクフィブロインを製膜する工程とを含んでいてもよい。
(Method of manufacturing silk fibroin film)
The method for producing a silk fibroin film may include an alkali treatment step of dissolving refined silk fibroin in a solvent and reacting it with an alkali treatment agent, and a step of forming a film from the alkali-treated silk fibroin.
シルクフィブロイン原料としては、昆虫(家蚕、野蚕、天蚕等の鱗翅目昆虫、スズメバチやミツバチ等の膜翅目昆虫等の絹糸昆虫)やクモ類が作る繭や生糸等を使用することができ、フィブロインおよびセリシンを含む絹原料であれば特に限定されない。絹原料を精練することにより、セリシンを除去したシルクフィブロインを得ることができる。また、絹糸腺からシルクフィブロインを得ることもできる。なお、精練は公知の方法で行うことができ、例えば、炭酸ナトリウムや珪酸ナトリウム、燐酸ナトリウム等のアルカリ精練剤を用いてセリシンを膨潤させて除去する方法や、セリシン分解酵素を用いてセリシンを分解させて除去する方法、セリシンを腐化させて除去する方法等の種々の方法が挙げられる。条件設定の簡便性の観点から、アルカリ精練剤を用いた精練が好ましい。精練では、セリシンの除去を主目的とし、シルクフィブロインの分解を抑制する観点から、アルカリ精練剤を用いた精練の時間は、絹原料やアルカリ精練剤の種類等に応じて異なるが、5~60分間であってもよく、好ましくは10~50分間、より好ましくは15~45分間であってもよい。 As the raw material for silk fibroin, cocoons and raw silk produced by insects (Lepidoptera insects such as domestic silkworms, wild silkworms, and wild silkworms, and silkworms producing insects such as hornets and honeybees producing insects such as hymenoptera insects) and spiders can be used, and there is no particular limitation as long as the raw material for silk contains fibroin and sericin. Silk fibroin from which sericin has been removed can be obtained by refining the raw silk material. Silk fibroin can also be obtained from silk glands. Refining can be performed by known methods, and examples of such methods include a method of removing sericin by swelling it using an alkaline refining agent such as sodium carbonate, sodium silicate, or sodium phosphate, a method of decomposing sericin using a sericin-degrading enzyme, and a method of removing sericin by decay. Refining using an alkaline refining agent is preferred from the viewpoint of ease of setting conditions. The main purpose of scouring is to remove sericin, and in order to suppress the decomposition of silk fibroin, the scouring time using an alkaline scouring agent varies depending on the type of silk raw material and alkaline scouring agent, but may be 5 to 60 minutes, preferably 10 to 50 minutes, and more preferably 15 to 45 minutes.
次に、精練されたシルクフィブロインをアルカリ処理に供することによって、シルクフィブロインを加水分解させて水溶性を向上させることができる。分子量調整の観点から、シルクフィブロインの加水分解はアルカリ処理工程で行うことが好ましい。アルカリ処理は、シルクフィブロインを溶媒に溶解させて、アルカリ処理剤(例えば、水酸化ナトリウムや水酸化カリウム等のアルカリ金属水酸化物やアンモニア等)と反応させることによって行うことができる。例えば、シルクフィブロインは、臭化リチウムや塩化カルシウム等の中性塩を含む中性塩溶液に溶解させてもよい。中性塩およびアルカリ処理剤を含む混合溶液を用いてシルクフィブロインを溶解させると共にアルカリ処理を行ってもよいし、中性塩溶液にシルクフィブロインを溶解させた後にアルカリ処理剤を加えてアルカリ処理を行ってもよい。 Next, the refined silk fibroin is subjected to an alkali treatment to hydrolyze the silk fibroin and improve its water solubility. From the viewpoint of molecular weight adjustment, it is preferable to carry out the hydrolysis of silk fibroin in an alkali treatment step. The alkali treatment can be carried out by dissolving silk fibroin in a solvent and reacting it with an alkali treatment agent (e.g., an alkali metal hydroxide such as sodium hydroxide or potassium hydroxide, or ammonia, etc.). For example, silk fibroin may be dissolved in a neutral salt solution containing a neutral salt such as lithium bromide or calcium chloride. Silk fibroin may be dissolved and alkali treatment may be carried out at the same time using a mixed solution containing a neutral salt and an alkali treatment agent, or silk fibroin may be dissolved in a neutral salt solution and then an alkali treatment agent may be added to carry out the alkali treatment.
中性塩の溶液中の濃度は、例えば、3~15M、好ましくは4~14M、より好ましくは3~12Mであってもよい。また、アルカリ金属水酸化物の溶液中の濃度は、例えば、0.05~2M、好ましくは0.08~1.5Mであってもよい。アンモニアの溶液中の濃度は、例えば、0.05~1.5M、好ましくは0.1~1Mであってもよい。 The concentration of the neutral salt in the solution may be, for example, 3 to 15 M, preferably 4 to 14 M, and more preferably 3 to 12 M. The concentration of the alkali metal hydroxide in the solution may be, for example, 0.05 to 2 M, and preferably 0.08 to 1.5 M. The concentration of ammonia in the solution may be, for example, 0.05 to 1.5 M, and preferably 0.1 to 1 M.
アルカリ処理を比較的マイルドな条件で行うことにより、重量平均分子量を効果的に低下させることができる。この時のアルカリ処理の温度は、40℃以下(例えば、5~40℃)であってもよく、好ましくは10℃~40℃、より好ましくは15℃~35℃であってもよい。また、アルカリ処理を施す時間は、3時間を超える時間であってもよく、好ましくは4時間以上、より好ましくは10時間以上、さらに好ましくは15時間以上であってもよい。アルカリ処理を施す時間の上限は特に限定されないが、例えば、48時間以下であってもよい。本明細書において、アルカリ処理を施す時間は、シルクフィブロインがアルカリ処理剤と接触している時間を意味し、例えば、中性塩およびアルカリ処理剤を含む混合溶液を用いる場合には、シルクフィブロインに混合溶液を加えて(またはシルクフィブロインを混合溶液に加えて)からの時間を示し、中性塩溶液にシルクフィブロインを溶解させた後にアルカリ処理剤を加える場合には、アルカリ処理剤を加えてからの時間を示す。 By carrying out the alkali treatment under relatively mild conditions, the weight-average molecular weight can be effectively reduced. The temperature of the alkali treatment may be 40°C or less (for example, 5 to 40°C), preferably 10°C to 40°C, and more preferably 15°C to 35°C. The time for carrying out the alkali treatment may be more than 3 hours, preferably 4 hours or more, more preferably 10 hours or more, and even more preferably 15 hours or more. The upper limit of the time for carrying out the alkali treatment is not particularly limited, but may be, for example, 48 hours or less. In this specification, the time for carrying out the alkali treatment means the time during which the silk fibroin is in contact with the alkali treatment agent. For example, when a mixed solution containing a neutral salt and an alkali treatment agent is used, it indicates the time from adding the mixed solution to the silk fibroin (or adding the silk fibroin to the mixed solution), and when an alkali treatment agent is added after dissolving the silk fibroin in a neutral salt solution, it indicates the time from adding the alkali treatment agent.
アルカリ処理によって得られたシルクフィブロインは、上述の範囲の各種分子量(Mw、Mn、PDIおよびMp)を有していてもよい。例えば、シルクフィブロインフィルムの製造方法は、重量平均分子量(Mw)が150kDa以下(好ましくは120kDa以下、より好ましくは100kDa以下、さらに好ましくは80kDa以下)であるシルクフィブロインを製膜する工程を含んでいてもよい。 The silk fibroin obtained by alkali treatment may have various molecular weights (Mw, Mn, PDI, and Mp) within the above-mentioned ranges. For example, the method for producing a silk fibroin film may include a step of forming a silk fibroin film having a weight-average molecular weight (Mw) of 150 kDa or less (preferably 120 kDa or less, more preferably 100 kDa or less, and even more preferably 80 kDa or less).
アルカリ処理後、例えば透析や限外濾過等の公知の方法で、中性塩やアルカリ処理剤の除去を行ってもよい。また、生体材料として使用する観点から、製膜(フィルム化)前に、中性塩やアルカリ処理剤以外にも不純物を除去するために、シルクフィブロインを精製したり、滅菌処理したりすることが好ましい。滅菌処理に関しては、オートクレーブ滅菌やフィルタ滅菌等の公知の方法を採用することができるが、オートクレーブ滅菌を行うことが好ましい。 After the alkaline treatment, the neutral salts and the alkaline treatment agent may be removed by known methods such as dialysis or ultrafiltration. From the viewpoint of using it as a biomaterial, it is preferable to purify and sterilize the silk fibroin before membrane formation (film formation) in order to remove impurities other than the neutral salts and the alkaline treatment agent. Regarding the sterilization, known methods such as autoclave sterilization and filter sterilization can be used, but autoclave sterilization is preferable.
シルクフィブロイン水溶液(好ましくは精製および/または滅菌処理後のシルクフィブロイン水溶液)を用いて製膜することによりシルクフィブロインフィルムを得ることができる。シルクフィブロイン水溶液は、所望のフィルムの厚さや物性等に応じて濃度を調整してもよく、例えば、シルクフィブロイン水溶液の濃度は、0.1~10%(w/v)であってもよく、好ましくは0.5~8%(w/v)、より好ましくは1~6%(w/v)であってもよい。 A silk fibroin film can be obtained by forming a membrane using an aqueous silk fibroin solution (preferably an aqueous silk fibroin solution after purification and/or sterilization). The concentration of the aqueous silk fibroin solution may be adjusted according to the desired thickness and physical properties of the film. For example, the concentration of the aqueous silk fibroin solution may be 0.1-10% (w/v), preferably 0.5-8% (w/v), and more preferably 1-6% (w/v).
シルクフィブロインは、キャスト法、コーティング法等の公知の製膜方法により製膜することができる。例えば、シルクフィブロイン水溶液を基材上に流延または塗布した後、乾燥させることによりシルクフィブロインフィルムを得ることができる。 Silk fibroin can be formed into a film by known film-forming methods such as casting and coating. For example, a silk fibroin film can be obtained by casting or applying an aqueous solution of silk fibroin onto a substrate and then drying it.
以下に、実施例に基づき本発明を更に詳細に説明するが、本発明はこれらにより何ら制限を受けるものではない。なお、以下の実施例及び比較例においては、下記の方法により各種物性を測定した。 The present invention will be described in more detail below with reference to examples, but the present invention is not limited by these examples. In the following examples and comparative examples, various physical properties were measured by the following methods.
[分子量]
濃度を1%(w/v)に調整したシルクフィブロイン水溶液500μLを測定試料とした。この測定試料を用いて、以下の測定装置および条件でゲル濾過クロマトグラフィー(GFC)により測定を行った。シルクフィブロインの重量平均分子量(Mw)、数平均分子量(Mn)、分子量分布(PDI)、およびピークトップ分子量(Mp)は、低分子用(LowMolecular Weight;LMW)Gel Filtration Calibration Kits、および高分子用(High Molecular Weight;HMW)Gel Filtration Calibration Kits(いずれもCytiva社製)に含まれる分子量マーカーを標準物質として用いて算出した。
・装置 :Cytiva社製GFC装置「AKTAgo」
・分離カラム :Cytiva社製「HiLoad16/600 Superdex 200pg」
・移動相 :500mM塩化ナトリウム含有20mMリン酸ナトリウム緩衝液(pH:7.4)
・流速 :1mL/min
・温度 :室温(24.0℃)以下、単に室温と称する場合は、24.0℃を代表値として用いる。
[Molecular weight]
The measurement sample was 500 μL of a silk fibroin aqueous solution adjusted to a concentration of 1% (w/v). Using this measurement sample, measurements were performed by gel filtration chromatography (GFC) using the following measurement device and conditions. The weight average molecular weight (Mw), number average molecular weight (Mn), molecular weight distribution (PDI), and peak top molecular weight (Mp) of silk fibroin were calculated using molecular weight markers included in the low molecular weight (Low Molecular Weight; LMW) Gel Filtration Calibration Kits and the high molecular weight (High Molecular Weight; HMW) Gel Filtration Calibration Kits (both manufactured by Cytiva) as standard substances.
Device: Cytiva GFC device "AKTAgo"
Separation column: Cytiva "HiLoad16/600 Superdex 200pg"
Mobile phase: 20 mM sodium phosphate buffer containing 500 mM sodium chloride (pH: 7.4)
・Flow rate: 1mL/min
Temperature: Room temperature (24.0°C) or lower. When simply referring to room temperature, 24.0°C is used as the representative value.
[フィルム表面の水溶性]
室内環境(温度22.4~29.1℃、湿度32~64RH)で一晩以上保管したシルクフィブロインフィルムに耐水性の油性ペン(water-resistant permanent marker)(ゼブラ株式会社製、商品名「マッキー極細」、黒色)で一辺1cmの正方形およびその対角線を描いた。なお、線の太さは約1mmであった。その正方形の線に沿ってフィルムを切り出し、縦1cm、横1cmのサンプル片を得た。室温下、シャーレに入れた超純水(24~28℃)に油性ペンで描いた面を上にしてサンプル片を浮かべた。浮かべた時点を起点として、油性ペンで描いた6本の直線(4つの辺、2つの対角線)が全て分断される時間を計測した。3つのサンプル片について測定し、油性ペンで描いた6本の直線が全て分断される時間の平均時間をフィルム表面が水に溶解する時間として算出した。1日以上経っても油性ペンで描いた6本の直線が分断されなかった場合は、フィルム表面が水に溶解しないと判断した。
[Water solubility of film surface]
A square with a side length of 1 cm and its diagonal line were drawn on the silk fibroin film stored overnight or more in an indoor environment (temperature 22.4-29.1°C, humidity 32-64 RH) with a water-resistant permanent marker (Zebra Corporation, product name "Mackie Extra Fine", black). The line thickness was about 1 mm. The film was cut along the lines of the square to obtain a sample piece with a length of 1 cm and a width of 1 cm. The sample piece was floated on ultrapure water (24-28°C) in a petri dish at room temperature with the side drawn with the oil pen facing up. Starting from the time of floating, the time until all six straight lines (four sides, two diagonals) drawn with the oil pen were broken was measured. Measurements were performed on three sample pieces, and the average time until all six straight lines drawn with the oil pen were broken was calculated as the time until the film surface dissolves in water. If the six straight lines drawn with an oil-based pen were not broken even after one day or more, it was determined that the film surface was not water-soluble.
[フィルムの水溶性]
室内環境で一晩以上保管したシルクフィブロインフィルムを切り出し、縦0.5cm、横0.5cmのサンプル片を得て、このサンプル片の重量を量った(この時の重量を「溶解前フィルム重量」とする)。チューブに入れた超純水1mLにサンプル片を浸漬し、25℃で1時間もしくは24時間インキュベートした。マイクロピペット(エッペンドルフ社製、「リファレンス2、4920000.083」)を用いて、溶け残ったフィルムをピペットチップ先端に吸い付け、予め重さ(この時の重量を「チューブ重量」とする)を量った2mL容量のチューブ内にフィルムを移した。なお、この時点でフィルムが確認できない場合は、水溶解率が100%とした。その後、50℃に設定した定温乾燥機(アズワン社製、「KM-600V」)内にチューブを静置して一晩インキュベートすることで、溶け残ったフィルムに保持された水分を蒸発させ、チューブと乾燥したシルクフィブロインフィルムとを合わせた重さを量った(この時の重量を「チューブ+乾燥フィルム重量」とする)。そして、下式に従ってシルクフィブロインフィルムの水溶解率(%)を算出した。
水溶解率(%)=100×[溶解前フィルム重量(mg)-{チューブ重量+乾燥フィルム重量(mg)-チューブ重量(mg)}]/溶解前フィルム重量(mg)
[Water solubility of film]
The silk fibroin film stored overnight or longer in an indoor environment was cut out to obtain a sample piece of 0.5 cm length and 0.5 cm width, and the weight of this sample piece was measured (the weight at this time was referred to as the "film weight before dissolution"). The sample piece was immersed in 1 mL of ultrapure water in a tube and incubated at 25°C for 1 hour or 24 hours. Using a micropipette (Eppendorf, "Reference 2, 4920000.083"), the remaining film was sucked onto the tip of the pipette tip, and the film was transferred to a 2 mL tube whose weight (the weight at this time was referred to as the "tube weight") had been measured in advance. If the film could not be confirmed at this point, the water solubility was taken as 100%. The tube was then left to stand in a constant temperature dryer (As One, "KM-600V") set at 50°C and incubated overnight to evaporate the moisture retained in the remaining film, and the weight of the tube and the dried silk fibroin film combined was measured (the weight at this time was referred to as the "tube + dried film weight"). The water solubility (%) of the silk fibroin film was then calculated according to the following formula.
Water solubility (%)=100×[film weight before dissolution (mg)−{tube weight+dry film weight (mg)−tube weight (mg)}]/film weight before dissolution (mg)
[水の接触角]
接触角計(エキシマ社製、「SImageAUTO100」)を用いて、室温下、JIS R 3257:1999の静滴法を参考にして、シルクフィブロインフィルムのフィルム表面上に約5μLの超純水の水滴を滴下し、接線法により測定された水の接触角の時間変化を測定した(測定間隔:1/15秒)。水滴を滴下した時点を0秒とし、30秒まで測定し、0~5秒における接触角の測定データを最小二乗法により直線近似し、得られた直線の傾きおよび切片を算出した。シルクフィブロインフィルムの3箇所について測定し、近似直線の傾きの平均値を接触角変化(°/sec)、切片の平均値をフィルム表面に水滴を滴下した時(0秒)の接触角(°)として算出した。
[Water contact angle]
Using a contact angle meter (manufactured by Excimer Corporation, "SImageAUTO100"), a droplet of about 5 μL of ultrapure water was dropped on the surface of the silk fibroin film at room temperature, referring to the sessile drop method of JIS R 3257:1999, and the change in the contact angle of water measured by the tangent method was measured over time (measurement interval: 1/15 seconds). The time when the droplet was dropped was set to 0 seconds, and measurements were made up to 30 seconds. The contact angle measurement data from 0 to 5 seconds was linearly approximated by the least squares method, and the slope and intercept of the obtained line were calculated. Measurements were made at three points on the silk fibroin film, and the average value of the slope of the approximated line was calculated as the contact angle change (°/sec), and the average value of the intercept was calculated as the contact angle (°) when the droplet was dropped on the film surface (0 seconds).
[含水率]
熱重量示差熱分析装置(TG-DTA;リガク社製、「Thermoplus TG8120」)を用いて、シルクフィブロインフィルムの含水率(%)を測定した。室内環境で一晩以上保管したシルクフィブロインフィルム試料2.5~8.5mgをアルミニウム製パンに入れ、窒素を200ml/minの流量で流し、30℃から10℃/minで昇温したときの重量変化を測定した。測定開始時(30℃)でのシルクフィブロインフィルムの重量(「試料重量」とする)と30~180℃の昇温過程で減少した重量(「水分重量」とする)を量った。そして、下式に従ってシルクフィブロインフィルムの含水率を測定した。これと同様にして、個別に調製した3つの試料のそれぞれについて測定し、これらの平均値をシルクフィブロインフィルムの含水率(%)として算出した。
含水率(%)=100×水分重量(mg)/試料重量(mg)
[Moisture content]
The moisture content (%) of the silk fibroin film was measured using a thermogravimetric differential thermal analyzer (TG-DTA; Rigaku Corporation, "Thermoplus TG8120"). Silk fibroin film samples (2.5 to 8.5 mg) stored overnight or longer in an indoor environment were placed in an aluminum pan, and nitrogen was passed through them at a flow rate of 200 ml/min. The weight change was measured when the temperature was raised from 30°C at 10°C/min. The weight of the silk fibroin film at the start of the measurement (30°C) (referred to as "sample weight") and the weight lost during the temperature rise from 30 to 180°C (referred to as "water weight") were measured. The moisture content of the silk fibroin film was then measured according to the following formula. In the same manner, measurements were performed on each of the three individually prepared samples, and the average value of these values was calculated as the moisture content (%) of the silk fibroin film.
Moisture content (%) = 100 x water weight (mg) / sample weight (mg)
[厚さ]
デジタルマイクロメーター(ニコン社製、「MFC-101A」)を用いて、シルクフィブロインフィルムの厚さ(μm)を測った。測定ヘッドが台座まで下りた状態でゼロ点設定を行った。その後、室内環境で一晩以上保管したシルクフィブロインフィルム試料を台座に置き、測定ヘッドを試料まで下ろしてシルクフィブロインフィルムの厚さを測定した。これと同様にして、個別に調製した3つの試料のそれぞれについて測定し、これらの平均値をシルクフィブロインフィルムの厚さ(μm)として算出した。
[Thickness]
The thickness (μm) of the silk fibroin film was measured using a digital micrometer (Nikon Corporation, "MFC-101A"). The zero point was set with the measurement head lowered to the pedestal. Then, the silk fibroin film sample stored overnight or longer in an indoor environment was placed on the pedestal, and the measurement head was lowered to the sample to measure the thickness of the silk fibroin film. In the same manner, measurements were taken for each of the three individually prepared samples, and the average value of these measurements was calculated as the thickness (μm) of the silk fibroin film.
[突刺し強度]
室内環境で一晩以上保管したシルクフィブロインフィルム試料を用いて、以下の測定装置および条件で突刺し強度(N)の測定を行った。これと同様にして、個別に調製した3つの試料のそれぞれについて測定し、これらの平均値をシルクフィブロインフィルムの突刺し強度(N)として算出した。
・装置:小型卓上試験機(島津製作所社製、「EZTest」)
・ロードセル容量:10N
・突刺し治具:直径φ3mm、先端角度60°
・突刺し速さ:50mm/min
・温度:室温
[Puncture strength]
The silk fibroin film samples stored overnight or longer in an indoor environment were used to measure the puncture strength (N) using the following measuring device and conditions. Similarly, measurements were performed on three individually prepared samples, and the average value was calculated as the puncture strength (N) of the silk fibroin film.
Equipment: Small tabletop tester (Shimadzu Corporation, "EZTest")
・Load cell capacity: 10N
- Piercing tool: diameter φ3mm,
Piercing speed: 50 mm/min
Temperature: Room temperature
[実施例1]
家蚕の繭を細断し、この繭を沸騰した0.02M炭酸ナトリウム水溶液中で30分間精練して、シルクフィブロインを得た。
[Example 1]
Silkworm cocoons were cut into pieces and degummed in a boiling 0.02 M aqueous solution of sodium carbonate for 30 minutes to obtain silk fibroin.
精練したシルクフィブロイン3gを、9M臭化リチウムと0.1M水酸化ナトリウム(NaOH)とを含有する混合水溶液(50mL)に浸し、室温で1~6時間放置した。次に、この混合水溶液を室温で17時間撹拌することで、シルクフィブロインを混合水溶液に溶解させるとともにアルカリ処理を行い、シルクフィブロイン水溶液を得た。 3 g of the refined silk fibroin was immersed in a mixed aqueous solution (50 mL) containing 9 M lithium bromide and 0.1 M sodium hydroxide (NaOH) and left at room temperature for 1 to 6 hours. Next, this mixed aqueous solution was stirred at room temperature for 17 hours, dissolving the silk fibroin in the mixed aqueous solution and subjecting it to an alkali treatment to obtain an aqueous silk fibroin solution.
得られたシルクフィブロイン水溶液を、透析膜(分画分子量:6-8k)を用いて脱イオン水中で透析した。1回の透析を、室温で6~12時間かけて行い、これを6回繰り返した(浴比:160倍)。これにより、シルクフィブロイン水溶液に含まれていた臭化リチウムおよび水酸化ナトリウムを除去した。 The obtained silk fibroin aqueous solution was dialyzed in deionized water using a dialysis membrane (molecular weight cutoff: 6-8k). Each dialysis was carried out at room temperature for 6-12 hours, and this was repeated six times (bath ratio: 160 times). This removed the lithium bromide and sodium hydroxide contained in the silk fibroin aqueous solution.
臭化リチウムおよび水酸化ナトリウムを除去した後のシルクフィブロイン水溶液を室温下で風乾することで濃縮した。風乾による濃縮は、シルクフィブロイン水溶液の体積が1/5~1/3になるまで行った。 After removing the lithium bromide and sodium hydroxide, the silk fibroin aqueous solution was concentrated by air drying at room temperature. Concentration by air drying was continued until the volume of the silk fibroin aqueous solution was reduced to 1/5 to 1/3.
濃縮後のシルクフィブロイン水溶液を、オートクレーブ装置(株式会社トミー精工製、「LBS-245」)を用いてオートクレーブ滅菌処理に供した。121℃、20分間のオートクレーブ滅菌処理を2回行った。以降の処理はいずれも滅菌状態で行った。 The concentrated silk fibroin aqueous solution was subjected to autoclave sterilization using an autoclave device (Tomy Seiko Co., Ltd., "LBS-245"). Autoclave sterilization was performed twice at 121°C for 20 minutes. All subsequent treatments were performed under sterile conditions.
オートクレーブ滅菌後のシルクフィブロイン水溶液を、遠心処理装置(BeckmanCoulter社製、「Avanti20I」)を用いて遠心処理(40000×g、20℃、30分間)し、沈殿した不溶物を除去した。 The silk fibroin aqueous solution after autoclave sterilization was centrifuged (40,000 x g, 20°C, 30 minutes) using a centrifuge (Beckman Coulter, "Avanti 20I") to remove precipitated insoluble matter.
不溶物を除去した後のシルクフィブロイン水溶液を凍結乾燥し、濃度が1%(w/v)となるように調整した。 After removing the insoluble matter, the silk fibroin aqueous solution was freeze-dried and the concentration was adjusted to 1% (w/v).
濃度を1%(w/v)に調整したシルクフィブロイン水溶液3mLをポリスチレン製シャーレ(内径5.4cm)に展開し、室温下で2日間以上静置することにより水分を蒸発させて、シルクフィブロインフィルムを得た。 3 mL of a silk fibroin aqueous solution adjusted to a concentration of 1% (w/v) was spread in a polystyrene petri dish (inner diameter 5.4 cm) and left at room temperature for at least 2 days to evaporate the water, yielding a silk fibroin film.
[実施例2]
凍結乾燥後、濃度が5%(w/v)となるようにシルクフィブロイン水溶液を調整し、そのシルクフィブロイン水溶液3mLをポリスチレン製シャーレに展開したこと以外は実施例1と同様にして、シルクフィブロインフィルムを得た。
[Example 2]
After freeze-drying, a silk fibroin aqueous solution was adjusted to a concentration of 5% (w/v), and a silk fibroin film was obtained in the same manner as in Example 1, except that 3 mL of the silk fibroin aqueous solution was spread in a polystyrene petri dish.
[実施例3]
凍結乾燥後、濃度が4%(w/v)となるようにシルクフィブロイン水溶液を調整し、そのシルクフィブロイン水溶液6mLをポリスチレン製シャーレに展開したこと以外は実施例1と同様にして、シルクフィブロインフィルムを得た。
[Example 3]
After freeze-drying, a silk fibroin aqueous solution was adjusted to a concentration of 4% (w/v), and a silk fibroin film was obtained in the same manner as in Example 1, except that 6 mL of the silk fibroin aqueous solution was spread in a polystyrene petri dish.
[実施例4]
凍結乾燥後、濃度が5%(w/v)となるようにシルクフィブロイン水溶液を調整し、そのシルクフィブロイン水溶液6mLをポリスチレン製シャーレに展開したこと以外は実施例1と同様にして、シルクフィブロインフィルムを得た。
[Example 4]
After freeze-drying, a silk fibroin aqueous solution was adjusted to a concentration of 5% (w/v), and a silk fibroin film was obtained in the same manner as in Example 1, except that 6 mL of the silk fibroin aqueous solution was spread in a polystyrene petri dish.
[実施例5]
凍結乾燥後、濃度が5%(w/v)となるようにシルクフィブロイン水溶液を調整し、そのシルクフィブロイン水溶液10mLをポリスチレン製シャーレに展開したこと以外は実施例1と同様にして、シルクフィブロインフィルムを得た。
[Example 5]
After freeze-drying, a silk fibroin aqueous solution was adjusted to a concentration of 5% (w/v), and a silk fibroin film was obtained in the same manner as in Example 1, except that 10 mL of the silk fibroin aqueous solution was spread in a polystyrene petri dish.
[比較例1]
精練済みのシルクフィブロイン3gを、NaOHを含有しない9M臭化リチウム水溶液(50mL)に浸したこと以外は実施例1と同様にして、シルクフィブロインフィルムを得た。
[Comparative Example 1]
A silk fibroin film was obtained in the same manner as in Example 1, except that 3 g of the refined silk fibroin was immersed in a 9 M lithium bromide aqueous solution (50 mL) that did not contain NaOH.
[比較例2]
精練済みのシルクフィブロイン3gを、NaOHを含有しない9M臭化リチウム水溶液(50mL)に浸したこと以外は実施例2と同様にして、シルクフィブロインフィルムを得た。
[Comparative Example 2]
A silk fibroin film was obtained in the same manner as in Example 2, except that 3 g of the refined silk fibroin was immersed in a 9 M lithium bromide aqueous solution (50 mL) that did not contain NaOH.
[比較例3]
精練済みのシルクフィブロイン3gを、NaOHを含有しない9M臭化リチウム水溶液(50mL)に浸したこと以外は実施例3と同様にして、シルクフィブロインフィルムを得た。
[Comparative Example 3]
A silk fibroin film was obtained in the same manner as in Example 3, except that 3 g of the refined silk fibroin was immersed in a 9 M lithium bromide aqueous solution (50 mL) that did not contain NaOH.
[比較例4]
精練済みのシルクフィブロイン3gを、NaOHを含有しない9M臭化リチウム水溶液(50mL)に浸したこと以外は実施例4と同様にして、シルクフィブロインフィルムを得た。
[Comparative Example 4]
A silk fibroin film was obtained in the same manner as in Example 4, except that 3 g of the refined silk fibroin was immersed in a 9 M lithium bromide aqueous solution (50 mL) that did not contain NaOH.
[比較例5]
精練済みのシルクフィブロイン3gを、NaOHを含有しない9M臭化リチウム水溶液(50mL)に浸したこと以外は実施例5と同様にして、シルクフィブロインフィルムを得た。
[Comparative Example 5]
A silk fibroin film was obtained in the same manner as in Example 5, except that 3 g of the refined silk fibroin was immersed in a 9 M lithium bromide aqueous solution (50 mL) that did not contain NaOH.
各実施例および比較例について、各種測定を行った結果を表1に示す。 The results of various measurements performed on each Example and Comparative Example are shown in Table 1.
表1に示すように、アルカリ処理を行った実施例1~5では、フィルム表面が短時間で水に溶解しているのに対して、比較例1~5では、フィルム表面が水に溶解していない。図1は、実施例4のシルクフィブロインフィルムのサンプル片を水に浮かべた直後および約3分後の状態を示す写真である。図2は、比較例4のシルクフィブロインフィルムのサンプル片を水に浮かべた直後および約8分後の状態を示す写真である。比較例1~5は、7日以上経っても油性ペンで描いた6本の直線が分断されなかった。 As shown in Table 1, in Examples 1 to 5 in which alkali treatment was performed, the film surface dissolved in water in a short time, whereas in Comparative Examples 1 to 5, the film surface did not dissolve in water. Figure 1 is a photograph showing the state immediately after and about 3 minutes after a sample piece of silk fibroin film of Example 4 was floated on water. Figure 2 is a photograph showing the state immediately after and about 8 minutes after a sample piece of silk fibroin film of Comparative Example 4 was floated on water. In Comparative Examples 1 to 5, six straight lines drawn with an oil-based pen were not broken even after more than 7 days.
また、実施例1~5と比較例1~5とで0秒での接触角に有意な差はないが、接触角変化は比較例1~5に比べて実施例1~5が小さい。これはフィルム表面の水溶性の違いによる影響と考えられる。アルカリ処理を行った実施例1~5では、比較例1~5と比較して分子量を低下できており、シルクフィブロインの分子量低下がフィルム表面の水溶性にも寄与していると考えられる。 In addition, there is no significant difference in the contact angle at 0 seconds between Examples 1 to 5 and Comparative Examples 1 to 5, but the change in contact angle is smaller in Examples 1 to 5 than in Comparative Examples 1 to 5. This is thought to be due to the difference in water solubility of the film surface. In Examples 1 to 5, which were subjected to alkali treatment, the molecular weight was reduced compared to Comparative Examples 1 to 5, and it is thought that the reduction in the molecular weight of silk fibroin also contributes to the water solubility of the film surface.
[ラット盲腸擦過モデルにおける癒着防止効果の評価]
ラット(SD、7週齢オス、日本SLC社)を2~2.5%イソフルラン吸入麻酔下で、開腹してラットの盲腸を露出させた。露出した盲腸の表面を乾燥したガーゼで50回擦ることで約1cm×2cmの擦過傷を形成した。次いで、腹壁の表面をピンセットでえぐることで約1cm×1cmの裂挫傷を形成した。その後、盲腸を腹腔内に戻し、盲腸表面および腹壁表面の傷同士の位置を合わせた。そして、フィルム状の癒着防止材(2cm×2cm)を盲腸表面および腹壁表面のそれぞれの傷に1枚ずつ貼付し、閉創した。フィルム状の癒着防止材には、実施例4のシルクフィブロインフィルム、比較例4のシルクフィブロインフィルム、セプラフィルム(Baxter社製)、およびテナリーフ(グンゼ株式会社製)を用いた。実施例4のシルクフィブロインフィルム、比較例4のシルクフィブロインフィルム、およびテナリーフを移植したラットはそれぞれ4匹、セプラフィルムを移植したラットは5匹準備した。また、生理食塩水3mLを腹腔内に投与したラットを4匹準備した。癒着防止材を適用して閉創したラット1匹毎にブプレノルフィン0.6μgを筋肉内注射した後、覚醒させた。そして、上記手術を施した2週間後に、ラットを安楽死させ、再び開腹して癒着の評価を行った。
[Evaluation of adhesion prevention effect in a rat cecal abrasion model]
A rat (SD, 7-week-old male, Japan SLC) was anesthetized with 2-2.5% isoflurane inhalation, and the rat's cecum was exposed by laparotomy. The surface of the exposed cecum was rubbed 50 times with dry gauze to form an abrasion wound of about 1 cm x 2 cm. Next, the surface of the abdominal wall was scooped with tweezers to form a laceration wound of about 1 cm x 1 cm. The cecum was then returned to the abdominal cavity, and the wounds on the cecum surface and abdominal wall surface were aligned. Then, one film-type adhesion inhibitor (2 cm x 2 cm) was attached to each of the wounds on the cecum surface and abdominal wall surface, and the wound was closed. The film-type adhesion inhibitors used were the silk fibroin film of Example 4, the silk fibroin film of Comparative Example 4, Seprafilm (manufactured by Baxter), and Tenalef (manufactured by Gunze Co., Ltd.). Four rats were prepared each with the silk fibroin film of Example 4, the silk fibroin film of Comparative Example 4, and Tenaleaf, and five rats were prepared with Seprafilm. Four rats were also prepared with 3 mL of saline administered intraperitoneally. Each rat was given 0.6 μg of buprenorphine intramuscularly after applying the adhesion inhibitor and closing the wound, and then awakened. Two weeks after the above surgery, the rats were euthanized and re-opened to evaluate adhesion.
癒着の評価は、目視での観察により行い、以下の癒着スコア0~5の6段階評価にてスコア判定を実施した。
0:癒着なし
1:薄い膜状の癒着
2:複数の薄い膜状の癒着
3:斑を伴う厚い癒着
4:面付着のある厚い癒着
5:非常に厚く新生血管を伴う癒着、または複数の面付着のある癒着
The adhesions were evaluated by visual observation and scored according to the following adhesion score of 0 to 5, which is a 6-level scale.
0: no adhesion; 1: thin membrane-like adhesion; 2: multiple thin membrane-like adhesions; 3: thick adhesions with spots; 4: thick adhesions with surface attachment; 5: very thick adhesions with neovascularization or multiple surface attachments
スコア判定後、盲腸のうち擦過傷を形成した部分と腹壁のうち列挫症を形成した部分を採取し、生理食塩水で洗浄した。採取した組織を10%中性緩衝ホルマリン液(富士フィルム和光純薬社製)に浸漬し、室温下で3日以上静置することで固定した。固定した組織をOCTコンパウンド(サクラファインテックジャパン社製)に包埋し、-20℃で凍結させた。その後、クライオスタット(ライカ社製、「CM3050S」)を用いて、組織を厚さ10~12μmに薄切し、APSコートスライドガラス(松波硝子社製)に接着させた。室温下で一晩乾燥させた後、95%(v/v)エタノール(富士フィルム和光純薬社製)に4℃で10分間浸漬し、室温下で乾燥させた。その後、室温下で、流水に2分間、マイヤーヘマトキシリン溶液(富士フィルム和光純薬社製)に10分間、流水に15分間、1%エオシンY溶液(富士フィルム和光純薬社製)に2分間、70%(v/v)エタノールに15秒間、99.5%エタノールに15秒間、キシレン(富士フィルム和光純薬社製)に1分間、キシレンに2分間順次浸漬し、ヘマトキシリン・エオシン染色を行った。染色した組織切片を封入剤(メルク社製、「エンテランニュー」)中に封入し、顕微鏡(キーエンス社製、「BZX710」)を用いて明視野像を観察した。 After scoring, the abraded parts of the cecum and the abdominal wall parts with lacerations were collected and washed with saline. The collected tissues were immersed in 10% neutral buffered formalin (Fujifilm Wako Pure Chemical Industries, Ltd.) and fixed by leaving them at room temperature for more than 3 days. The fixed tissues were embedded in OCT compound (Sakura Finetech Japan Co., Ltd.) and frozen at -20°C. The tissues were then sliced to a thickness of 10-12 μm using a cryostat (Leica, "CM3050S") and attached to APS-coated glass slides (Matsunami Glass Co., Ltd.). After drying overnight at room temperature, the tissues were immersed in 95% (v/v) ethanol (Fujifilm Wako Pure Chemical Industries, Ltd.) at 4°C for 10 minutes and dried at room temperature. Thereafter, the sections were immersed in running water for 2 minutes, Mayer's hematoxylin solution (Fujifilm Wako Pure Chemical Industries, Ltd.) for 10 minutes, running water for 15 minutes, 1% eosin Y solution (Fujifilm Wako Pure Chemical Industries, Ltd.) for 2 minutes, 70% (v/v) ethanol for 15 seconds, 99.5% ethanol for 15 seconds, xylene (Fujifilm Wako Pure Chemical Industries, Ltd.) for 1 minute, and xylene for 2 minutes at room temperature to perform hematoxylin-eosin staining. The stained tissue sections were mounted in mounting medium (Merck, "Entelaneu") and bright field images were observed using a microscope (Keyence, "BZX710").
図4は、各癒着防止材における癒着スコア判定結果を示す箱ひげ図である。具体的には、生理食塩水(Saline)は、4匹のラットの癒着スコアが0点、1点、4点、4点であり、平均癒着スコアが2.25点であった。比較例4のシルクフィブロインフィルム(HMW)は、4匹のラットの癒着スコアが2点、3点、5点、0点であり、平均癒着スコアが2.50点であった。実施例4のシルクフィブロインフィルム(LMW)は、4匹のラットの癒着スコアが0点、0点、0点、4点であり、平均癒着スコアが1.00点であった。セプラフィルム(Seprafilm)は、6匹のラットのうち2匹が移植後3日以内に死亡し、4匹の癒着スコアが0点、0点、5点、0点であり、平均癒着スコアが1.25点であった。テナリーフ(Tenaleaf)は、5匹のラットのうち1匹が移植後3日以内に死亡し、3匹の癒着スコアが0点、3点、3点、0点であり、平均癒着スコアが1.50点であった。 Figure 4 is a box plot showing the adhesion score results for each adhesion prevention material. Specifically, for saline, the adhesion scores for four rats were 0, 1, 4, and 4, with an average adhesion score of 2.25. For the silk fibroin film (HMW) of Comparative Example 4, the adhesion scores for four rats were 2, 3, 5, and 0, with an average adhesion score of 2.50. For the silk fibroin film (LMW) of Example 4, the adhesion scores for four rats were 0, 0, 0, and 4, with an average adhesion score of 1.00. For Seprafilm, two of the six rats died within three days after implantation, and the adhesion scores for four rats were 0, 0, 5, and 0, with an average adhesion score of 1.25. In the case of Tenaleaf, one of the five rats died within three days of implantation, and the adhesion scores of three rats were 0, 3, 3, and 0, with an average adhesion score of 1.50.
癒着防止材の癒着スコア評価結果では、実施例4のシルクフィブロインフィルム(LMW)が比較例4のシルクフィブロインフィルム(HMW)よりも平均癒着スコアが優れた結果を示しており、癒着防止効果を示すことがわかる。図5は、実施例4のシルクフィブロインフィルムを移植して2週間後の盲腸および腹壁(癒着スコア:0)を示す写真である。実施例4のシルクフィブロインフィルムを適用した場合、2週間後にはフィルムの残存が確認されず、生体に分解吸収されたことがわかる。図6は、比較例4のシルクフィブロインフィルムを移植して2週間後の盲腸および腹壁(癒着スコア:5)を示す写真であり、図7は、その癒着部を示す写真である。比較例4のシルクフィブロインフィルムを適用した場合、癒着部にしこりができており、内部にフィルムの残存が確認され、生体に分解吸収されていなかった(図7)。 In the adhesion score evaluation results of the adhesion prevention material, the silk fibroin film of Example 4 (LMW) showed a better average adhesion score than the silk fibroin film of Comparative Example 4 (HMW), demonstrating the adhesion prevention effect. Figure 5 is a photograph showing the cecum and abdominal wall (adhesion score: 0) two weeks after implantation of the silk fibroin film of Example 4. When the silk fibroin film of Example 4 was applied, no film was found to remain after two weeks, indicating that the film had been decomposed and absorbed by the body. Figure 6 is a photograph showing the cecum and abdominal wall (adhesion score: 5) two weeks after implantation of the silk fibroin film of Comparative Example 4, and Figure 7 is a photograph showing the adhesion area. When the silk fibroin film of Comparative Example 4 was applied, a lump was formed at the adhesion area, and the film was found to remain inside, indicating that the film had not been decomposed and absorbed by the body (Figure 7).
また、比較例4のシルクフィブロインフィルムは参考例としての生理食塩水よりも平均癒着スコアが劣っていることから、単にシルクフィブロインを含むというだけでは癒着防止効果を発揮できないことが示されている。 In addition, the silk fibroin film of Comparative Example 4 had a lower average adhesion score than the physiological saline solution used as a reference example, indicating that simply containing silk fibroin is not enough to achieve adhesion prevention effects.
さらに、実施例4のシルクフィブロインフィルムは、市販のフィルム状の癒着防止材であるセプラフィルムおよびテナリーフよりも平均癒着スコアが優れた結果を示している。また、原因は不明であるが、セプラフィルムおよびテナリーフを適用したラットの中には、移植後3日以内に死亡したラットがいたが、実施例4のシルクフィブロインフィルムでは、死亡したラットはおらず、安全性にも優れることが示唆される。 Furthermore, the silk fibroin film of Example 4 showed a better average adhesion score than the commercially available film-type adhesion prevention materials Seprafilm and Tenaleaf. Also, although the cause is unknown, some rats that received Seprafilm and Tenaleaf died within three days after transplantation, whereas no rats died after receiving the silk fibroin film of Example 4, suggesting that it is also safe.
図8、図9は、それぞれ、比較例1の生理食塩水(Saline)および比較例4のシルクフィブロインフィルム(HMW)を裂挫傷に適用して2週間後の腹壁(AW)および盲腸(C)の状態を示す染色写真である。図8および図9に示すように、腹壁および盲腸は互いに癒着し、一体化していた。 Figures 8 and 9 are stained photographs showing the condition of the abdominal wall (AW) and cecum (C) two weeks after applying saline (Saline) of Comparative Example 1 and silk fibroin film (HMW) of Comparative Example 4 to the laceration wound, respectively. As shown in Figures 8 and 9, the abdominal wall and cecum had adhered to each other and were integrated.
一方、図10は、実施例4のシルクフィブロインフィルム(LMW)を裂挫傷に適用して2週間後の腹壁(AW)および盲腸(C)の状態を示す染色写真である。図10に示すように、腹壁および盲腸は、互いに離れており、癒着した箇所は見られなかった。 On the other hand, Figure 10 is a stained photograph showing the condition of the abdominal wall (AW) and cecum (C) two weeks after the silk fibroin film (LMW) of Example 4 was applied to the laceration. As shown in Figure 10, the abdominal wall and cecum were separated from each other, and no adhesions were observed.
また、図11および12は、それぞれ、市販のセプラフィルム(Seprafilm)およびテナリーフ(Tenaleaf)を裂挫傷に適用して2週間後の腹壁(AW)および盲腸(C)の状態を示す染色写真である。図11および図12に示すように、市販の癒着防止材を用いた場合も、腹壁および盲腸は、互いに離れており、癒着した箇所は見られなかった。 Figures 11 and 12 are stained photographs showing the condition of the abdominal wall (AW) and cecum (C) two weeks after the application of commercially available Seprafilm and Tenaleaf, respectively, to the laceration. As shown in Figures 11 and 12, even when the commercially available adhesion barrier was used, the abdominal wall and cecum remained separated from each other and no adhesions were observed.
したがって、本発明に係るシルクフィブロインフィルムは、市販のフィルム状の癒着防止材と同等以上の癒着防止効果を示すことが組織学的にも確認できた。一方、シルクフィブロインを用いているにもかかわらず、比較例4のシルクフィブロインフィルムは、癒着防止効果を示すことができなかった。 Therefore, it was histologically confirmed that the silk fibroin film according to the present invention exhibited an adhesion prevention effect equal to or greater than that of commercially available film-type adhesion prevention materials. On the other hand, despite the use of silk fibroin, the silk fibroin film of Comparative Example 4 failed to exhibit an adhesion prevention effect.
以上より、in vivo試験での評価結果により、本発明に係るシルクフィブロインフィルムは、市販のフィルム状の癒着防止材と同等以上の癒着防止効果を示すことが確認され、また、移植後2週間以内に生体に分解吸収されることも確認され、癒着防止材として有用であることがわかる。 From the above, the evaluation results of the in vivo test confirmed that the silk fibroin film of the present invention exhibits adhesion prevention effects equal to or greater than those of commercially available film-type adhesion prevention materials, and was also confirmed to be decomposed and absorbed by the body within two weeks after implantation, demonstrating its usefulness as an adhesion prevention material.
本発明のシルクフィブロインフィルムは、消化器外科、心臓外科、整形外科、産婦人科等(特に消化器外科および産婦人科)の臨床分野における種々の手術において、癒着が生じ得るあらゆる組織や臓器の癒着防止のために癒着防止材として用いることができる。 The silk fibroin film of the present invention can be used as an adhesion prevention material to prevent adhesion of any tissue or organ where adhesion may occur in various surgeries in the clinical fields of gastrointestinal surgery, cardiac surgery, orthopedic surgery, obstetrics and gynecology, etc. (particularly gastrointestinal surgery and obstetrics and gynecology).
以上のとおり、本発明の好適な実施例を説明したが、当業者であれば、本件明細書を見て、自明な範囲内で種々の変更および修正を容易に想定するであろう。
したがって、そのような変更および修正は、請求の範囲から定まる発明の範囲内のものと解釈される。
Although the preferred embodiments of the present invention have been described above, those skilled in the art will easily imagine various changes and modifications within the obvious scope upon reading this specification.
Therefore, such changes and modifications are intended to be within the scope of the invention as defined by the claims.
Claims (11)
ルクフィブロインである、シルクフィブロインフィルム。 The silk fibroin film according to any one of claims 1 to 5, wherein the silk fibroin present on the film surface is silk fibroin that is not modified with polyethylene glycol.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024555973A JP7688877B1 (en) | 2023-08-29 | 2024-06-13 | Silk fibroin film and anti-adhesion material containing same |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023-139250 | 2023-08-29 | ||
| JP2023139250 | 2023-08-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2025047047A1 true WO2025047047A1 (en) | 2025-03-06 |
Family
ID=94818921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2024/021523 Pending WO2025047047A1 (en) | 2023-08-29 | 2024-06-13 | Silk fibroin film and anti-adhesion material containing same |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP7688877B1 (en) |
| WO (1) | WO2025047047A1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008173312A (en) * | 2007-01-19 | 2008-07-31 | National Institute Of Agrobiological Sciences | Protein film production method and protein film obtained thereby |
| JP2016531943A (en) * | 2013-09-30 | 2016-10-13 | シルク セラピューティクス, インコーポレイテッド | Silk protein fragment composition and articles made therefrom |
| KR101927419B1 (en) * | 2017-06-09 | 2018-12-10 | 한림대학교 산학협력단 | Antiadhesive reagent containing silk fibroin |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7381860B2 (en) * | 2018-12-11 | 2023-11-16 | セントラル硝子株式会社 | Method for producing silk fibroin molded body |
-
2024
- 2024-06-13 WO PCT/JP2024/021523 patent/WO2025047047A1/en active Pending
- 2024-06-13 JP JP2024555973A patent/JP7688877B1/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008173312A (en) * | 2007-01-19 | 2008-07-31 | National Institute Of Agrobiological Sciences | Protein film production method and protein film obtained thereby |
| JP2016531943A (en) * | 2013-09-30 | 2016-10-13 | シルク セラピューティクス, インコーポレイテッド | Silk protein fragment composition and articles made therefrom |
| KR101927419B1 (en) * | 2017-06-09 | 2018-12-10 | 한림대학교 산학협력단 | Antiadhesive reagent containing silk fibroin |
Non-Patent Citations (2)
| Title |
|---|
| KAWANO, YUSUKE ET AL.: "Development of a novel anti-adhesion material using silk fibroin gel", PROGRAMS AND ABSTRACTS OF THE 42ND ANNUAL MEETING OF THE RESEARCH SOCIETY FOR ORTHOPAEDIC BIOMATERIALS, November 2023 (2023-11-01), pages 33, XP009560056 * |
| YAMAMOTO, HARUKA ET AL.: "Fabrication and Evaluation of Adhesion Preventive Film based on a Silk Fibroin with High Flexibility", PREPRINTS OF 2021 THE SOCIETY OF FIBER SCIENCE AND TECHNOLOGY, JAPAN, vol. 76, no. 1, 2 June 2021 (2021-06-02), pages 1, XP009560054 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7688877B1 (en) | 2025-06-05 |
| JPWO2025047047A1 (en) | 2025-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101610268B1 (en) | Surgical hydrogel | |
| US8912168B2 (en) | Modified starch material of biocompatible hemostasis | |
| EP2203053B1 (en) | Modified starch material of biocompatible hemostasis | |
| CN104981259B (en) | Kit comprising the aquagel membrane for preventing adhesion | |
| EP3470093A1 (en) | Tissue plug | |
| US20090214667A1 (en) | Medical technical product, method for producing the same and providing the same for surgery | |
| Hu et al. | An asymmetric Janus membrane with anti-bacteria adhesion and rapid hemostasis properties for wound healing | |
| JP2024515141A (en) | PTMC-based bioabsorbable flexible elastomeric intestinal anastomosis stent and method for its manufacture | |
| RU2509784C2 (en) | Method of producing porous, film-type materials based on carboxymethyl cellulose | |
| JP7688877B1 (en) | Silk fibroin film and anti-adhesion material containing same | |
| JP3560916B2 (en) | Methods and compositions for preventing postoperative adhesion and tissue damage in surgical procedures using fluorinated polymers | |
| JPH08157378A (en) | Preventing agent for adhesion | |
| EP1543846A1 (en) | Albumin-based bioresorbable cross-linked hydrogel | |
| WO2006136870A1 (en) | Bioresorbable hydrogel | |
| JP2003019194A (en) | Co-crosslinked gel composition comprising hyaluronic acid and carboxymethyl cellulose | |
| CN104826092A (en) | Intestinal adhesion prevention membrane solution as well as preparation method and application thereof | |
| WO2024195261A1 (en) | Silk fibroin gel for adhesion prevention material, method for producing same, adhesion prevention material, and adhesion prevention method | |
| KR20160142758A (en) | Manufacturing method of collagen film using ultraviolet rays and collagen film manufactured by using the same and biomaterials manufactured by using the collagen film | |
| Winkler | Bioinspired Adhesives for Fetal Membrane Presealing | |
| HK40048337A (en) | Tissue plug | |
| Esser | Adhesive polymer films for the prevention of postsurgical adhesions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ENP | Entry into the national phase |
Ref document number: 2024555973 Country of ref document: JP Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2024555973 Country of ref document: JP |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 24859093 Country of ref document: EP Kind code of ref document: A1 |
